This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nigro, J. Articles by Little, P. J. Search for Related Content PubMed PubMed Citation Articles by Nigro, J. Articles by Little, P. J.

Insulin Resistance and Atherosclerosis

Cell Biology of Diabetes Laboratory (J.N., N.O., P.J.L.), Baker Heart Research Institute, Melbourne 3181, Australia; Monash University, Departments of Immunology (N.O., P.J.L.) and Medicine (A.M.D., P.J.L.), Central and Eastern Clinical School, Alfred Hospital, Melbourne 3181, Australia; and Alfred Baker Medical Unit (A.M.D., P.J.L.), The Heart Centre, Alfred Hospital, Melbourne 3181, Australia

Correspondence: Address all correspondence and requests for reprints to: A/Prof. Peter J. Little, Head, Cell Biology of Diabetes Laboratory, Baker Heart Research Institute, Courier address: 75 Commercial Road, Prahran, 3181 Melbourne, VIC, Australia; Postal address: St. Kilda Road Central, P.O. Box 6492, Melbourne, VIC 8008, Australia. E-mail: peter.little{at}baker.edu.au

	Abstract

Top Abstract I. Introduction II. Pathology of Atherosclerosis III. Biochemical and Cellular... IV. Metabolic Pathophysiology of... V. Inflammation, Insulin... VI. Normal Insulin Receptor... VII. Insulin Signaling and... VIII. Abnormal Signaling in... IX. Conclusions, Implications,... References

 
The epidemic of obesity in the developed world over the last two decades is driving a large increase in type 2 diabetes and consequentially setting the scene for an impending wave of cardiovascular morbidity and mortality. It is only now being recognized that the major antecedent of type 2 diabetes, insulin resistance with its attendant syndrome, is the major underlying cause of the susceptibility to type 2 diabetes and cardiovascular disease.

In metabolic tissues, insulin signaling via the phosphatidylinositol-3-kinase pathway leads to glucose uptake so that in insulin resistance a state of hyperglycemia occurs; other factors such as dyslipidemia and hypertension also arise. In cardiovascular tissues there are two pathways of insulin receptor signaling, one that is predominant in metabolic tissues (mediated by phosphatidylinositol-3-kinase) and another being a growth factor-like pathway (mediated by MAPK); the down-regulation of the former and continued activity of the latter pathway leads to atherosclerosis.

This review addresses the metabolic consequences of the insulin resistance syndrome, its relationship with atherosclerosis, and the impact of insulin resistance on processes of atherosclerosis including insulin signaling in cells of the vasculature.

I. Introduction

II. Pathology of Atherosclerosis

III. Biochemical and Cellular Mechanisms of Atherosclerosis

IV. Metabolic Pathophysiology of Insulin Resistance Relevant to Atherosclerosis

V. Inflammation, Insulin Resistance, and Atherosclerosis

VI. Normal Insulin Receptor Signaling in Metabolic Tissues

VII. Insulin Signaling and Cellular Responses in Vascular Tissues

A. Endothelium

B. Vascular smooth muscle cells

C. Monocyte/macrophages

D. T lymphocytes

VIII. Abnormal Signaling in Insulin Resistance in Vascular Tissues

IX. Conclusions, Implications, and Speculations

	I. Introduction

Top Abstract I. Introduction II. Pathology of Atherosclerosis III. Biochemical and Cellular... IV. Metabolic Pathophysiology of... V. Inflammation, Insulin... VI. Normal Insulin Receptor... VII. Insulin Signaling and... VIII. Abnormal Signaling in... IX. Conclusions, Implications,... References

 
DEVELOPING AN UNDERSTANDING of the molecular basis underlying the physiological phenomena of insulin resistance and its pathological sequelae of cardiovascular disease is one of the major imperatives facing human disease in the area of endocrinology and metabolism.

The discovery of insulin by Banting and Best (1) in the early 1920s was a milestone of medical research in the 20th century and resulted in the award of a Nobel Prize in medicine. The discovery and then availability of insulin coupled several decades later by the development of bioassays for insulin (2) allowed for two major findings. The first is that the hyperglycemia of diabetes had two distinct origins occurring in the absence and presence of circulating insulin, leading to the postulation of two forms of diabetes first proposed by Himsworth (3) and later confirmed by Bornstein and Lawrence (4). These two forms marked by nominally zero and high levels of insulin were earlier known as juvenile-onset and maturity-onset diabetes but are now termed type 1 and type 2 diabetes, respectively (5, 6). The second major finding was that the response or sensitivity of individuals to the glucose-lowering action of insulin could vary greatly (7, 8). This variability in insulin sensitivity led to the recognition of the existence of insulin resistance (part of the cause of type 2 diabetes). It was later established that insulin resistance clusters with a variety of risk factors for cardiovascular disease—dyslipidemia, hypertension, and hypercoagulability—which are physiological/metabolic disturbances that form a syndrome known as syndrome X, the metabolic syndrome, or the insulin-resistance syndrome (9, 10). Hu et al. (11) discuss the multiple definitions of insulin resistance and the insulin-resistance/metabolic syndrome. The insulin-resistance syndrome is tightly coupled to obesity, and the consequences of body composition were first noted by Vague in 1947 (cited in Ref. 12). Under the societal influences of the last century, the consequences of body composition may have remained a small phenomena of marginal interest. However, the altered lifestyles in Western and now in developing countries, which have led to an explosion in the proportion of the population with obesity, is driving an increase in the prevalence of insulin resistance, the insulin-resistance syndrome, and type 2 diabetes, and it is widely predicted that this will be followed by an increasing burden of premature cardiovascular disease. The underlying pathology of premature cardiovascular disease is atherosclerosis, known traditionally as macrovascular disease in the setting of diabetes.

A primary biochemical abnormality in most cases of type 2 diabetes appears to be insulin resistance, although its cause(s) and effects are far from well understood. The onset of insulin resistance commonly leads to relative insulin deficiency with a slow decline in the regulation of blood glucose with hyperinsulinemia and elevated circulating free fatty acid (FFA) levels. This is followed by a later decrease in the ability to control plasma glucose manifest as rising fasting plasma glucose or rising peak plasma glucose levels in response to an oral glucose challenge with intermittent and persistent hyperglycemia leading to a diagnosis of type 2 diabetes. From this natural history of disease perspective, in genetically susceptible people, type 2 diabetes can be seen as end-stage insulin resistance. Although the molecular mechanism(s) of insulin resistance is unknown, it undoubtedly occurs directly or indirectly in insulin-sensitive tissues most closely associated with glucose homeostasis including the liver, skeletal muscle, and fat. Whether or not insulin resistance occurs and how it might be manifest in the critical tissues of cardiovascular disease—the heart and vasculature—is controversial.

The proposition considered in this review is that insulin resistance is the primary biochemical defect underlying the current epidemic of obesity with cardiovascular disease and type 2 diabetes. If insulin resistance is the primary biochemical defect, then it will follow that lifestyle (13, 14) and pharmacological strategies that address insulin resistance, that is interventions that increase insulin sensitivity, may represent the most logical and ultimately effective therapeutic response. An older agent, the biguanide metformin, acts as an insulin sensitizer predominantly by reducing insulin resistance in the liver (15). Metformin therapy was associated with beneficial outcomes in the UK Prospective Diabetes Study (16). The thiazolidinediones or glitazones, which are peroxisome proliferator-activated receptor- ligands, have emerged in the last decade (17, 18). These agents ameliorate insulin resistance and have direct antiatherogenic vascular actions (19, 20). The potential role of thiazolidinediones in the prevention of cardiovascular disease has been reviewed elsewhere (21). The role of drugs improving insulin resistance is acknowledged but will not be the focus of this review. This review will focus on the metabolic and vascular pathology and biochemical mechanisms of insulin resistance and the association of these factors with the development of atherosclerosis and cardiovascular disease in susceptible subjects.

	II. Pathology of Atherosclerosis

Top Abstract I. Introduction II. Pathology of Atherosclerosis III. Biochemical and Cellular... IV. Metabolic Pathophysiology of... V. Inflammation, Insulin... VI. Normal Insulin Receptor... VII. Insulin Signaling and... VIII. Abnormal Signaling in... IX. Conclusions, Implications,... References

 
Vascular disease in diabetes is usually differentiated as microvascular and macrovascular disease, where the former is associated with diabetic retinopathy and renal disease and the latter with the consequences of medium-large vessel disease including ischemic coronary, cerebrovascular, and peripheral arterial disease. The metabolic syndrome, prediabetes, and type 2 diabetes, which all cosegregate with insulin resistance, clearly accelerate vascular disease and increase the consequential disease burden (22) (Fig. 1). The exact mechanisms for the increased susceptibility and progression of atherosclerosis in patients with diabetes are unknown. However, although patients with diabetes show more advanced lesion development (23), the macroscopic/microscopic appearances of atherosclerotic lesions are generally similar between patients with and without diabetes.

View larger version (33K): [in this window] [in a new window]   FIG. 1. Natural history of insulin resistance and type 2 diabetes. The initial stages of insulin resistance are influenced by genetic factors and environmental factors with metabolic/physiological changes in insulin levels, lipids, and blood pressure. During the initial insulin-resistant period, or "Pre-diabetes," the metabolic and physiological changes proceed in parallel with the commencement of silent atherosclerosis and cardiovascular complications (this is depicted by the white- light red area to the left of the complications section) in genetically susceptible people, before the onset of diabetes. The onset of diabetes involves the clinical presentation of hyperglycemia and hyperinsulinemia as well as the metabolic/physiological disturbances present in insulin resistance and the acceleration of macrovascular and microvascular complications, the latter being exacerbated by hyperglycemia. The microvascular and macrovascular complications are the major causes of morbidity and mortality in patients with diabetes. The diagram indicates that atherosclerosis and cardiovascular disease commence before the formal onset of diabetes—this period is thus termed pre-cardiovascular disease ("Pre-CVD"). HDL, High-density lipoprotein; sd LDL, small dense LDL; IFG, impaired fasting glucose; IGT, impaired glucose tolerance.

	III. Biochemical and Cellular Mechanisms of Atherosclerosis

Top Abstract I. Introduction II. Pathology of Atherosclerosis III. Biochemical and Cellular... IV. Metabolic Pathophysiology of... V. Inflammation, Insulin... VI. Normal Insulin Receptor... VII. Insulin Signaling and... VIII. Abnormal Signaling in... IX. Conclusions, Implications,... References

 
The study of the pathways and mechanisms of atherosclerosis in cell and animal models has given considerable insight into the underlying processes, but a considerable amount needs to be determined in relation to critical steps that may be subject to therapeutic interruption.

Over the last century, various hypotheses have been forwarded to explain the initiating events and factors that contribute to the development of atherosclerosis. There are three major hypotheses of atherogenesis, which have some common and distinct components, and they include the response-to-injury hypothesis, response-to-retention hypothesis, and the oxidation hypothesis.

Russell Ross (31, 32) is highly regarded for his enunciation of the response-to-injury hypothesis, which states that endothelial damage precedes SMC migration and proliferation, deposition of intracellular and extracellular lipid, and accumulation of extracellular matrix. Subsequently, the response-to-injury hypothesis was broadened to include endothelial dysfunction as a key event that initiates the inflammatory mechanisms associated with atherosclerosis (33). The endothelium is a dynamic monolayer lining the blood vessel wall and is responsible for maintaining vascular tone through the production of vasodilators [e.g., nitric oxide (NO)] and vasoconstrictors (e.g., endothelin-1). As well as its vasodilation properties, NO regulates SMC migration and growth and inhibits inflammation and platelet aggregation. The endothelium releases other factors, such as von Willebrand factor, plasminogen inhibitors, and prostacyclin, that regulate thrombosis by inhibiting platelet aggregation. It is the imbalance between the effects of vasodilators and vasoconstrictors and inhibition of the anticlotting mechanisms that contribute to and characterize endothelial dysfunction.

Beginning in 1995, the work of various groups was articulated by Kevin J. Williams and Ira Tabas (34, 35) as the response-to-retention hypothesis, which proposes that the central atherogenic process is the subendothelial retention and accumulation of lipoproteins by extracellular matrix molecules, such as proteoglycans. The importance of this hypothesis was strongly supported by the work of Jan Boren and colleagues (36), who showed that mice expressing genetically modified ApoB that had defective binding of low-density lipoprotein (LDL) to proteoglycans developed atherosclerosis at a rate that was appreciably less than those mice expressing normal ApoB and thus normal LDL-proteoglycan binding.

The oxidation hypothesis of atherosclerosis was affirmed by Joseph L. Witztum in 1994 (37). The central component of the oxidation hypothesis is the oxidative modification of LDL, which acts as an immunogenic stimulus for monocyte recruitment to the vessel wall and phagocytic uptake of oxidized LDL (oxLDL) by macrophages. The process of oxidation of cellular components and particles such as lipoproteins is thought to exacerbate atherosclerosis, although this is generally a feature of late-stage lesions (37, 38).

oxLDL dissociates from the proteoglycans and acts as a strong inflammatory stimulus in the vessel wall. The presence of oxLDL provokes a series of cellular reactions involving monocyte/macrophages, endothelial cells, SMCs, and (CD4⁺) immune cells. Selectins (P, E, and L) on the monocyte cell surface assist their rolling and tethering over the endothelium by binding to the P-selectin ligand on the endothelial cell surface (39). The movement of monocytes is stopped by intercellular adhesion molecule (ICAM)-1, vascular adhesion molecule (VCAM)-1, and integrins followed by monocyte attachment to hyaluronan cable structures through CD44 (40), which facilitates transendothelial migration and the presentation of monocyte/macrophages to the cells and lipid in the vessel wall. Adiponectin inhibits the production of integrins and P-selectin, a mechanism that may act to regulate the recruitment of inflammatory cells to the vessel wall. A reduction in adiponectin induced by oxidative stress may exacerbate monocyte adhesion to the vascular endothelium.

The atherosclerotic lesion propagates through a series of cell-cell and cell-lipid interactions, leading to inflammation, extracellular matrix alterations, and necrosis. Subsequently, the weakening and rupture of the cap of the atherosclerotic plaques, possibly by matrix metalloproteinases (MMPs) such as MMP-9, leads to plaque rupture, thrombus formation, lumen obstruction, and the acute clinical events of a heart attack or ischemic stroke. The major initiating factors for atherosclerosis are the modification of the extracellular matrix, particularly the glycosaminoglycan chains on proteoglycans that attract and bind atherogenic lipoproteins, and the inflammatory processes involving the binding of monocytes to the vessel wall, cell penetration, differentiation into macrophages, lipid engulfment, and foam cell formation. A schematic representation of the atherogenic cascade is shown in Fig. 2. The figure depicts the normal process of LDL transitioning through a nondiseased vascular media (Fig. 2A) and the binding and retention of modified atherogenic LDL and subsequent formation of monocyte/macrophage foam cells in a diseased vessel wall (Fig. 2B).

View larger version (64K): [in this window] [in a new window]   FIG. 2. Hormonal and cellular mechanisms of atherosclerosis within the vessel wall. The diagrams are representations of transverse sections of a coronary blood vessel under physiological (A) and pathological (B) conditions. A, Physiological conditions. The cellular layers from the top down include the endothelium, media, and adventitia, with an internal elastic lamina between the endothelium and media layers. The media layer is comprised of well-oriented layers of SMCs. SMCs maintain tone and also synthesize matrix molecules including proteoglycans. Proteoglycans consist of a core protein (green) and one or more glycosaminoglycan (GAG) chains, which are heavily sulfated and thus negatively charged (represented as blue chains on the green core protein). The proteoglycans in the image have two GAG chains and thus represent biglycan, a major type of proteoglycan found in human vessels. Circulating lipoproteins in the blood such as normal LDL (>25 nm diameter, orange molecules) freely traverse the blood vessel wall a, Normal proteoglycans; b, normal LDL. B, Pathological conditions. Atherogenic stimuli associated with the metabolic syndrome (reactive oxygen species and inflammatory cytokines) arising from redox alterations in adipose tissues precipitate a metabolic abnormality in the vascular endothelium (endothelial dysfunction) and a cascade of events within the neointima of the vessel wall. The neointima (NI) is a less organized and morphologically distinct layer. Intimal SMCs secrete proteoglycans with one or more structural changes in the biochemical properties of the GAG chains (red extension of blue chain). Biochemically altered proteoglycans are more likely to bind and retain lipoprotein particles. In the case of patients with diabetes, the atherogenic lipid profile includes an increased number of small dense LDL (<25 nm diameter, pink molecules) particles that have a greater propensity to penetrate the vessel wall and a higher affinity binding for proteoglycans compared with normal LDL (178 ). The combination of altered proteoglycans and the abundance of small dense LDL leads to the entrapment of the positively charged LDL in the subendothelial space. Retained LDL particles are susceptible to oxidation and protein modification. oxLDL (yellow molecules) has a lower affinity for proteoglycans compared with normal LDL and is released from the proteoglycan GAG chains. The presence of oxLDL triggers an immunological response whereby circulating monocytes bind to the endothelium via adhesion molecules and possibly through the interaction of CD44 receptors with hyaluronan (green molecule extruding from the endothelium), a GAG without a core protein that acts as a CD44 ligand. Hyaluronan is synthesized on VSMCs and endothelial cells by hyaluronan synthase (represented by green oblongs on SMC). Monocytes traverse the endothelium and differentiate into macrophages that then entrap and attempt to remove the LDL. The presence of LDL overwhelms the macrophages, which are unable to phagocytose the LDL and the lipid-laden macrophages or foam cells (yellow cells on the right) are deposited in the subendothelial space. The atherosclerotic process continues over many years, and the complex lesion may weaken, rupture, and form a thrombus, which would then occlude the lumen and reduce blood flow to the heart causing a myocardial infarction. a, Endothelial dysfunction resulting from metabolic disturbances such as hypercholesterolemia and reactive oxygen species; b, proteoglycans; c, normal LDL; d, migrating and proliferating VSMCs; e, modified proteoglycan; f, small dense LDL bound to proteoglycans; g, oxLDL is released from the protoeglycans; h, monocytes bind to the endothelium via adhesion molecules and possibly interact with hyaluronan; i, lipid-laden foam cells.

	IV. Metabolic Pathophysiology of Insulin Resistance Relevant to Atherosclerosis

Top Abstract I. Introduction II. Pathology of Atherosclerosis III. Biochemical and Cellular... IV. Metabolic Pathophysiology of... V. Inflammation, Insulin... VI. Normal Insulin Receptor... VII. Insulin Signaling and... VIII. Abnormal Signaling in... IX. Conclusions, Implications,... References

 
The spectrum of metabolic disturbances associated with insulin resistance extends beyond hyperglycemia and includes dyslipidemia, hypercoagulability, and inflammation. The importance of the insulin resistance syndrome is reflected in its recognition as the cornerstone of what is termed the insulin-resistance syndrome, syndrome X, or metabolic syndrome (10). Although the metabolic syndrome is becoming part of the obesity lexicon, it should be noted that there is controversy over the question of whether or not the metabolic or insulin-resistant syndrome is actually a syndrome if the use of syndrome implies a mechanistic link that draws the relevant parameters together (9, 46). The metabolic syndrome predicts higher levels of cardiovascular disease, but the question is whether or not the prediction has any stronger value than considering the aggregate effect of the individual risk factors. The major evidence for the existence of a mechanistically linked syndrome is that the cardiovascular risk factors occur together or cluster more often than predicted by chance (47). Further basic and clinical research will undoubtedly shed light on this intriguing and important question.

Obesity, and central obesity in particular, is a major underlying factor in insulin resistance. Insulin resistance in fat cells leads to increased lipolysis and the release of FFA. Some 40 yr ago, Randle et al. (48) proposed that insulin resistance occurs as a result of fatty acid oxidation, leading to inactivation of mitochondrial pyruvate dehydrogenase and ultimately decreased glucose uptake, and this was based on work in isolated rat heart. However, it would appear that glucose metabolism, including the role of insulin, can vary markedly between tissues. In skeletal muscle there is an apparently straightforward process of glucose uptake, mediated by glucose transporters, phosphorylation to glucose-6-phosphate by hexokinase, and further processing leading to storage as glycogen catalyzed by glycogen synthase. People with diabetes lose efficiency in passing glucose to glycogen such that the ability to store glycogen can be reduced by 60%. Both glucose transporters and hexokinase play a critical role in glucose uptake because it is the gradient of the parent chemical entity that determines the rate of influx. The phosphorylation of glucose by hexokinase greatly reduces the intracellular glucose concentration (to 100–200 µM), creating a large inward gradient for influx through the glucose transporter. Nevertheless, Cline et al. (49) have concluded that the glucose transporter GLUT4 is the rate-limiting step in insulin-stimulated glycogen synthesis. Increases in plasma fatty acid levels can inhibit glucose transport and hexokinase activity, implying that fatty acids can inhibit signaling through the insulin receptor.

The liver is the major site of glucose uptake and storage as well as insulin clearance. Insulin suppresses glucose production by the liver directly by binding to the insulin receptor on hepatocytes and inhibiting both glycogenolysis and gluconeogenesis. An indirect effect of insulin via suppressing lipolysis in adipose tissue is less FFA delivery to the liver with less glycogenolysis and less hepatic insulin resistance. Insulin is the major hormone responsible for maintaining energy homeostasis by coordinating the use of fat deposits not only in liver but also in muscle and adipose tissue. Adipose tissue stores FFAs as triglycerides and also releases FFAs and adipokines including leptin, adiponectin, resistin, plasminogen activator inhibitor (PAI)-1, and TNF-. The acute response (90 min) of islets treated with FFAs is to amplify glucose-stimulated insulin secretion, a response that is mediated by the G protein-coupled receptor 40 (50). However, in human studies the insulin secretion rate is reduced by 30% in patients with type 2 diabetes infused with FFAs for 4 h compared with subjects without diabetes (51). The chronic treatment (3–7 d) of normal rat pancreatic islets (52) and rat insulinoma cell lines (53) with FFA in vitro decreases glucose-stimulated insulin secretion. Additionally, the 7-d treatment of fat-laden islets isolated from Zucker diabetic fatty rats with FFAs reduces glucose-stimulated insulin secretion (54). Leptin has been reported to have a role in insulin resistance via the adrenergic system and by acting directly on peripheral tissues (55). Mice deficient in leptin are hyperglycemic and hyperinsulinemic and leptin administration reverses these changes without altering weight, suggesting it may have an effect on insulin resistance independent of weight control (56). Adipose tissue TNF- levels correlate with body fat and hyperinsulinemia in mice and have been shown to play a part in insulin resistance. The role of TNF- in human insulin resistance is still to be clarified. In contrast, human plasma adiponectin levels are clearly negatively correlated with insulin resistance and have a stronger link to insulin resistance than body fat levels. Circulating levels of adiponectin, particularly the higher-molecular-weight glycosylated forms, may be a useful marker of insulin resistance and angiopathy (55).

	V. Inflammation, Insulin Resistance, and Atherosclerosis

Top Abstract I. Introduction II. Pathology of Atherosclerosis III. Biochemical and Cellular... IV. Metabolic Pathophysiology of... V. Inflammation, Insulin... VI. Normal Insulin Receptor... VII. Insulin Signaling and... VIII. Abnormal Signaling in... IX. Conclusions, Implications,... References

 
Insulin resistance, inflammation, and atherosclerosis appear to be linked via the metabolic syndrome, and the question is the nature of the association being either a common molecular pathology related to insulin receptor signaling or vascular consequences of metabolic abnormalities of insulin resistance. Some very important findings have emerged recently and provide biochemical linkages between obesity and insulin resistance and atherosclerosis. In mice, fat-derived cytokines activate the nuclear factor-B signaling pathway in hepatocytes, and mimicking this activation by selectively expressing constitutively active IB kinase-ß in hepatocytes generates systemic insulin resistance most likely through the generation and actions of proinflammatory cytokines including IL-6 and TNF- (57). In humans and mice, increasing obesity is associated with increased oxidative stress in the fat compartment and in circulating markers of oxidative stress (58). There are two potential mechanisms: the deregulated production of pro- and antiinflammatory cytokines and the elevated levels of systemic oxidative stress mediated through increased oxidative enzymes (nicotinamide adenine dinucleotide phosphate, reduced, oxidase) and decreased antioxidative enzymes (superoxide dismutase). Thus, obesity-derived proinflammatory cytokines and reactive oxygen species can generate peripheral insulin resistance but also directly impact on the endothelium to cause endothelial dysfunction and initiate the atherosclerotic cascade (see Fig. 2).

These studies provide a link between obesity and insulin resistance in metabolic tissues. Although the metabolic consequences are almost certainly proinflammatory for the vasculature, whether or not the changes have generated insulin resistance in cardiovascular tissues remains unresolved. Furthermore, the application and appreciation of the expression of deleterious inflammatory processes in the cardiovascular system is relatively new (33), and the cellular mechanisms linking cytokines with the role of the immune system in cardiovascular disease requires further consideration.

Inflammation is a term taken from other areas of medicine and applied recently to cardiovascular disease (33, 59, 60). It is poorly defined in its new context and confuses bloodborne and other factors from tissue sources that may be biomarkers or effectors of cardiovascular disease. We would take a narrow view of inflammation to be the binding, penetration, and proliferation of monocyte/macrophages in the vessel wall to destroy and remove deleterious stimuli, i.e., the process is vessel healing. However, when there is a secondary stimulus such as hyperlipidemia, the immunological response may become overloaded or chronic and the process of atherosclerosis is initiated. Many factors are then activated as a response to the initial insult. This insult may be insulin resistance, and insulin resistance is associated with elevated levels of inflammatory markers. The extensive range of inflammatory markers and effectors associated with insulin resistance and the impact of insulin resistance on their relevant parameters is documented in Table 1.

	VI. Normal Insulin Receptor Signaling in Metabolic Tissues

Top Abstract I. Introduction II. Pathology of Atherosclerosis III. Biochemical and Cellular... IV. Metabolic Pathophysiology of... V. Inflammation, Insulin... VI. Normal Insulin Receptor... VII. Insulin Signaling and... VIII. Abnormal Signaling in... IX. Conclusions, Implications,... References

 
The insulin receptor plays a crucial role in mediating the effects of insulin including the rapid stimulation of glucose uptake (via the glucose transporter protein GLUT4) into its target metabolic tissues, muscle and fat. The insulin receptor is a transmembrane receptor tyrosine kinase (61) able to form homo- or heterodimers with the IGF receptor (IGFR) as disulfide-linked ₂ß₂ tetramer proteins. Insulin binds with high affinity to the -subunit of the insulin receptor, leading to subsequent autophosphorylation of the ß-subunits on three intracellular tyrosine residues (62). Under physiological conditions, each receptor responds only to its own ligand (63). Under some circumstances, IGF-I appears to have metabolic effects similar to insulin (64).

The insulin receptor ß-subunits are also subjected to intracellular Ser/Thr phosphorylation by protein kinase C (PKC) (65) and dephosphorylation by protein tyrosine phosphatases. Studies in mice deficient in protein tyrosine phosphatase-1B have shown that this enzyme plays a key role in attenuating the insulin receptor response (66). The insulin receptor phosphorylates at least nine intracellular signaling molecules including four intracellular insulin receptor substrates (IRS proteins IRS-1, -2, -3, -4). Studies with transgenic mice suggest that most insulin responses are mediated via IRS1 or IRS2 (67, 68). Phosphorylated tyrosine residues on each of these substrate proteins enables docking of a distinct subset of downstream signaling molecules containing Src-homology-2 domains. Docking proteins include the p85 regulatory subunit of phosphatidylinositol-3-kinase [PI (3)K]; adapter proteins Grb2, Nck, and Shc (69, 70); protein tyrosine phosphatase src homology protein tyrosine phosphatase 2; and the tyrosine kinase fyn (71). The diversity of these proteins enables the downstream signals to be amplified and diversified by serving as common substrates for a number of receptors and thus integrating signals from several signaling cascades (67). Insulin receptor docking proteins also serve as points of alteration in insulin receptor signaling efficiency.

In metabolic tissues, PI (3)K plays a central role in insulin-stimulated glucose uptake (see Fig. 3). Activation of PI (3)K generates phosphatidylinositol-3,4,5-triphosphate (72), which activates the serine/threonine phosphoinositide-dependent kinase kinase 1 (PDK1) and also activates an unidentified kinase, which together phosphorylate the highly conserved Thr³⁰⁸ and Ser⁴⁷³ residues, respectively, present in the serine/threonine kinase Akt/protein kinase B (73). Atypical PKC and PKC isoforms are also activated by PI (3)K and phosphoinositide-dependent kinase kinase 1 and have been shown to be required for insulin-stimulated glucose transport. The importance of Akt in glucose homeostasis has been demonstrated in Akt2^–/– mice (Akt2 predominates in insulin-responsive tissues) that exhibit insulin resistance and glucose intolerance due to elevated hepatic glucose output and reduced glucose uptake in skeletal muscle (74). Recently, a negative modulator of Akt has been identified and termed TRB3 (previously known as NIPK); it is induced in liver under fasting conditions and disrupts insulin signaling by binding directly to Akt and blocking activation of the kinase (75). Interference with Akt activation may contribute to insulin resistance in individuals with susceptibility to type 2 diabetes.

View larger version (29K): [in this window] [in a new window]   FIG. 3. Insulin receptor signaling and the points of interaction causing atherosclerosis related to insulin resistance. Insulin resistance in metabolic tissue manifests as a down-regulation of the PI (3)K pathway leading to hyperglycemia and other components of the metabolic syndrome. Extrapolation from numerous in vitro studies leads to speculation that insulin resistance in vascular tissue causes down-regulation of the PI (3)K pathway, whereas the MAPK pathway proceeds unabated, with consequential proatherogenic effects. It is clear from the figure that insulin resistance in metabolic and vascular tissues leads to proatherogenic outcomes. EC, Endothelial cell.

	VII. Insulin Signaling and Cellular Responses in Vascular Tissues

Top Abstract I. Introduction II. Pathology of Atherosclerosis III. Biochemical and Cellular... IV. Metabolic Pathophysiology of... V. Inflammation, Insulin... VI. Normal Insulin Receptor... VII. Insulin Signaling and... VIII. Abnormal Signaling in... IX. Conclusions, Implications,... References

 
In most mammalian tissues, a significant fraction of both insulin receptor and IGFR occur as hybrids and form the majority of receptors in cardiac and skeletal muscle (76). In human endothelial cells, IGFR expression exceeds insulin receptor expression (64). Although insulin signaling is focused on metabolic pathways, IGF signals are directed to regulating cell proliferation, cell survival, and differentiation. In differentiated VSMCs, IGF-I activates the PI (3)K/Akt pathway and activation of SHP-2 blocks the MAPK cascade; however, in dedifferentiated VSMCs, e.g., in vascular injury, IGF-I activates ERK and MAPK via Grb2/Sos and Ras, resulting in proliferation and migration (77). A role for IGF in cell proliferation and differentiation has also been reported in hemopoietic cells and adipocytes (78, 79). The elements that control the balance between signaling through the PI (3)K and MAPK pathways may indicate trigger points in insulin resistance. IGF-I is increased in vessels after balloon-injury (80, 81). Thus, the vascular responses to both high concentrations of insulin (as occurs in insulin resistance) and IGF-I may be contributing factors to vascular disease. Of direct importance to cellular mechanisms of atherosclerosis is the relationship between circulating insulin levels and levels affecting the cells of the vasculature. Fasting plasma insulin levels in normal insulin-sensitive people are in the low picomolar range (50–150 pM) (82, 83). By definition, insulin levels are higher in subjects with insulin resistance and in type 2 diabetes and plasma levels in the nanomolar range (up to 1.5 nM) are observed (83). Although there are issues such as tissue concentration and penetration with respect to comparing circulating levels of agents with concentrations displaying actions in vitro, it is nevertheless potentially informative. By way of example, insulin has an antiatherogenic action (84) to inhibit the synthesis of the glycosaminoglycan hyaluronan (85) by human aortic SMCs with an efficacy of 60% and half-maximal effect at approximately 500 pM. Insulin (600 pM) treatment of intact rat aorta ex vivo enhances leptin-mediated relaxation as well as Akt phosphorylation and NO production (86). Thus, plasma insulin concentrations associated with insulin resistance are in the concentration range that affects vascular cell and tissue responses in vitro and ex vivo.

The major cells involved in atherosclerosis are endothelial cells, VSMCs, monocytes/macrophages, and T lymphocytes, and the following section considers insulin signaling pathways in each of these cell types.

A. Endothelium
Insulin receptors on human endothelial cells from the umbilical vein were initially identified and characterized by ¹²⁵I-insulin receptor binding studies almost 30 yr ago (87). The number of insulin receptors present on endothelial cells can differ depending on whether the cells are derived from human umbilical arteries, which have more insulin receptors compared with endothelial cells derived from human umbilical veins (88).

Stimulation of insulin receptors in endothelial cells activates the PI (3)K pathway, suggesting that these receptors are similar to those found in metabolic tissues. In contrast to skeletal muscle, insulin treatment of bovine aortic endothelial cells does not promote glucose conversion to glycogen, suggesting that these cells express little or no glycogen synthase (89). Endothelial cells from bovine aorta and human umbilical vein show no mitogenic response to insulin treatment (89).

In contrast to metabolic tissues, stimulation of the PI (3)K pathway in endothelial cells leads to an increase in the expression of the constitutively active endothelial NO synthase (eNOS) both in vivo and in cultured endothelial cells (90). A study using overexpression of the insulin receptor and an inactive form of the insulin receptor in cultured human umbilical vein endothelial cells has elucidated part of the insulin signaling cascade related to increased NO production (91). Insulin receptor activation leads to tyrosine phosphorylation of the insulin receptor and activation of Akt the serine/threonine kinase downstream of PI (3)K (91). Down-regulation of Ras, an upstream mediator of MAPK signaling has little effect on NO production by endothelial cells treated with insulin, suggesting that PI (3)K/Akt signaling is required for insulin receptor-mediated NO production in endothelial cells (91). Additionally, insulin-stimulated eNOS expression, protein, and activity are decreased in the presence of synthetic inhibitors of PI (3)K, wortmannin and LY294002 (90). Stimulation of eNOS by insulin treatment can be attenuated by the concomitant treatment with angiotensin II, which increases the phosphorylation of serine residues in preference to tyrosine residues on IRS-1, decreasing the interaction between IRS-1 and p85 [PI (3)K subunit] and reduces PI (3)K/Akt/eNOS signaling (92).

NO stimulates guanylate cyclase, the enzyme that converts GTP to cGMP. cGMP lowers intracellular free calcium, promotes vasodilatation, inhibits VSMC proliferation, and regulates angiogenesis (93). Thus, the production of NO by endothelial cells is viewed as a potentially vascular protective mechanism. Insulin and IGF-I increase the production of NO in endothelial cells by directly increasing eNOS, which converts L-arginine to NO and L-citrulline products (94). Insulin stimulates both eNOS expression and activity through the PI (3)K pathway (90, 91, 95).

Subjects with insulin resistance, type 2 diabetes, or other components of the metabolic syndrome demonstrate a phenomenon termed "endothelial dysfunction," which is at least partly a result of decreased production or increased clearance of NO and thus impaired blood flow (96). Insulin-resistant patients display reduced vasodilatation response to cold pressor testing, indicating endothelial dysfunction (97). Family members of patients with type 2 diabetes also commonly have endothelial dysfunction (98).

Vascular endothelial cell insulin receptor knockout mice show normal vascular development; however, the expression of eNOS and endothelin-1 are significantly reduced in the heart and aorta (99). Mice with targeted disruption of the eNOS gene develop peripheral and metabolic insulin resistance (100). These two studies highlight the importance of maintaining a balance between NO and insulin for endothelial function. Conversely, others have recently found that insulin resistance does not alter the expression of eNOS in an animal model of the metabolic syndrome (101).

The production of NO by endothelial cells stimulated by insulin/IGF leads to a group of antiatherogenic effects including both antiinflammatory and antithrombotic mechanisms involved in atherogenesis. Antiinflammatory effects of NO include a decrease in expression of the adhesion molecules VCAM-1, ICAM-1, E-selectin, and a decrease in the secretion of proinflammatory cytokines monocyte chemoattractant protein-1 and TNF- (102). Antithrombotic effects include a decrease in platelet adhesion (103) and increased prostacyclin production, which inhibits platelet aggregation (104).

Endothelial cell migration and proliferation is considered an antiatherogenic response to vascular injury such as hypertension, cigarette smoking, hypercholesterolemia, or hemodynamic stress, as an intact and active endothelium promotes vascular quiescence and vessel healing (105). Endothelial cell migration is induced by IGF-I and can be inhibited by the PI (3)K inhibitor LY294002 but not the MAPK inhibitor PD98059, suggesting that the PI (3)K pathway mediates IGF-I-stimulated endothelial cell migration (106). In an in vitro model of compensatory hyperinsulinemia, endothelial cells treated with insulin in the presence of a PI (3)K inhibitor wortmannin demonstrate activation of the MAPK pathway and downstream cellular effects such as increased DNA synthesis, increased expression of VCAM-1 and E-selectin, and increased interaction with monocytes (107). The interaction of endothelial cells with inflammatory cells may also be mediated by the extracellular matrix molecule hyaluronan, which is a ligand for CD44 receptor-positive inflammatory cells (108). Wistar rats fed a fructose diet to induce the metabolic disturbances of type 2 diabetes, i.e., insulin resistance and hyperinsulinemia, show an increase in hyaluronan deposition after balloon-injury (109). An interesting extension of this work would be to determine whether or not insulin mediates hyaluronan synthesis in cultured endothelial cells and thus alters monocyte/macrophage adhesion through the CD44 binding mechanism (Fig. 3).

Endothelin-1 is a 21-amino-acid peptide that is secreted by endothelial cells and induces proatherogenic effects such as vasoconstriction (110), increased vascular permeability (111), VSMC proliferation (112), increased production of IL-6 by endothelial cells and monocytes (113, 114), and increased proteoglycan synthesis by VSMCs (M. E. Ivey and P. J. Little, unpublished observations). In contrast, antiatherogenic actions of endothelin-1 include the stimulation of NO production (115). Sprague-Dawley rats with mild diabetes that were treated with high doses of insulin for 10 d showed an increase in plasma endothelin levels (116). Insulin-treated bovine aortic endothelial cells increase the expression and secretion of endothelin-1 in a concentration- and time-dependent manner (116). The stimulation of endothelin-1 secretion by insulin treatment of endothelial cells is not imitated by IGF-I treatment, and insulin-mediated endothelin-1 secretion is inhibited by genistein, a broad inhibitor of tyrosine kinases, suggesting that insulin mediates the increase in ET-1 through the insulin receptor (116). It is presently unclear whether or not the regulation of endothelin-1 expression by insulin is via the PI (3)K pathway or the MAPK pathway, and this remains an important and interesting pathway to elucidate.

B. Vascular smooth muscle cells
The presence of insulin receptors in human VSMCs was demonstrated in 1983 by ¹²⁵I-insulin binding studies (89). Both insulin and IGF-I receptors are present on rat SMCs, and these receptors are distinct from each other in terms of binding affinity of insulin and IGF-I (117). In rat SMCs, insulin has an affinity for the insulin receptor that is 1000 times that of IGF-I and IGF-I has an affinity for the IGF-I receptor that is 500 times that of insulin for the IGF-I receptor (117). Insulin and IGF-I receptors on VSMCs can be distinguished from each other using specific antibodies (118).

The insulin receptors on VSMCs are structurally and functionally similar to those in metabolic tissues (119). The number of insulin receptors is 10-fold lower in bovine aortic SMCs compared with bovine aortic endothelial cells (89). Vascular SMCs and metabolic cells show a difference in the predominant type of glucose transporter expressed (GLUT1 in vascular cells and GLUT4 in skeletal muscle). Insulin stimulation of glucose transport by GLUT1 in vascular cells appears to occur in a similar manner to the PI (3)K pathway-mediated glucose transport by GLUT4 in metabolic cells, except that GLUT1 is less dynamically translocated than GLUT4.

Insulin signaling mechanisms in VSMCs are similar to those in endothelial cells in that insulin binds to the insulin/IGF-I receptor, leading to tyrosine phosphorylation of the ß-subunit on the insulin receptor. The insulin receptor then phosphorylates tyrosine residues on the insulin receptor substrates (IRS-1–IRS-4). IRS-1 and IRS-2 can activate PI (3)K/Akt or the RASRAFMEKKMAPKc-fos cascade. Insulin signaling in VSMCs initiates proatherogenic cellular events such as proliferation and migration. Insulin-mediated bovine VSMC migration is inhibited by PD 98059 (MAPK inhibitor) but not wortmannin [PI (3)K inhibitor], implying that insulin-mediated activation of the MAPK pathway mediates VSMC migration (120). This is in contrast to IGF-I-mediated migration, which occurs mainly through the activation of PI (3)K (Fig. 3) (121).

Bovine VSMCs show a 3-fold increase in a mitogenic response to insulin compared with endothelial cells (89). Insulin-stimulated VSMC mitogenesis is mainly controlled through the MAPK pathway; however, the PI (3)K pathway also contributes to maintaining VSMC quiescence (120, 122). Similar to insulin, IGF-I also stimulates VSMC proliferation mainly through the MAPK pathway (121). Activation of MAPK leads to the proliferation and migration of VSMCs, which are somewhat simplistically referred to as proatherogenic cellular processes (105). Evidence suggesting that MAPK is a target for insulin-mediated proliferation and migration was shown in in vitro studies using PD 98059, an inhibitor of the MAPK pathway (122). Treatment of rat SMCs with PD 98059 inhibits the mitogenic response to insulin in a concentration-related manner (122). Additionally, insulin-treated bovine SMCs in the presence of wortmannin show reduced quiescence, suggesting that PI (3)K is involved in maintaining SMCs in the quiescent state and that blocking the PI (3)K pathway (as would occur in insulin resistance) allows insulin to activate the MAPK pathway to induce proliferation and migration responses (120).

Insulin acts synergistically with other atherogenic growth factors such as platelet-derived growth factor (PDGF) to promote the proliferation and migration of bovine aortic SMCs via a c-myc-dependent pathway (123). This may occur in parallel with the effect of insulin to induce VSMC quiescence through the activation of the PI (3)K pathway, which can inhibit PDGF-induced proliferation of VSMCs, but the PI (3)K pathway may be blunted in insulin resistance, and thus the PDGF and insulin combination would be proatherogenic (120). Insulin and angiotensin II have an additive effect to increase MAPK in mesangial cells, which have VSMC-like morphological characteristics (124). Similar to the effect of angiotensin II on endothelial cells, angiotensin II treatment of SMCs inhibits the association of p85 with PI (3)K and thus inhibits insulin-mediated PI (3)K signaling, representing a mechanism for insulin resistance after activation of the renin-angiotensin system (125).

Insulin at supraphysiological concentrations is more effective than IGF-I in inducing a mitogenic response in VSMCs (126); however, the growth effects of insulin and IGF-I are mediated through the IGF-I receptor, not the insulin receptor (118). There is no additive effect of insulin with IGF-I on VSMC mitogenesis (123). There are varied reports regarding whether or not hyperinsulinemia regulates aortic expression of the IGF-I receptor, with some showing that IGF-I receptors are increased in rats with diabetes given insulin (127) and others reporting that insulin-treated rats with diabetes have reduced aortic expression of IGF-I (128). Despite these different findings, it appears that insulin mediates proatherogenic effects in VSMCs, at least in part through the IGF-I receptor.

NO synthesis by VSMCs is regulated by inducible NO synthase (iNOS). Insulin treatment of rat SMCs increases iNOS protein, and insulin-mediated iNOS induction can be inhibited by both PI (3)K and MAPK inhibitors, wortmannin and PD98059, respectively. NO appears to both inhibit the migration of late-passage VSMCs (129) and promote the migration of primary cultured VSMCs (130). Similarly, NO has been shown to stimulate the proliferation of primary rat VSMCs (131, 132) and to inhibit DNA synthesis of later-passaged VSMCs (93, 133). The effects of NO on SMCs are mediated by cGMP-dependent protein kinase G (PKG). Estimation of NO effects in SMCs by PKG-dependent mechanisms is underestimated and compromised in in vitro studies because cGMP PKG is lost in cultured VSMCs after three passages, and this possibly accounts for the conflicting observations of primary vs. cultured VSMCs (134). Insulin and NO treatment of primary rat VSMCs has an additive effect on increasing cell migration, and cell movement is further enhanced when VSMCs are treated with insulin, NO, and PDGF (135). The effects of insulin on VSMC migration are attributed to the insulin receptor, not the IGF-I receptor (135). NO-induced VSMC migration occurs through the MAPK pathway (136), and insulin- plus NO-induced VSMC migration is dependent on the interaction of src homology protein tyrosine phosphatase 2 with the adapter protein Gab1, both of which are upstream mediators of MAPK (135). Insulin- and NO-induced VSMC migration can be inhibited by LY294002, the PI (3)K inhibitor, suggesting that both the MAPK and the PI (3)K pathways are involved in insulin- plus NO-mediated VSMC migration (135).

Targeted disruption of components of the insulin signaling cascade modulates the response to vascular injury in vivo. IRS-2 knockout mice show increased neointima formation after balloon-injury, indicating that IRS-2 has a protective role against neointimal damage, possibly because it is an upstream mediator of PI (3)K/Akt signaling (137).

Treatment of bovine VSMCs with insulin (10 µg/ml) increases glycogen synthesis by 250% (89). Insulin-treated VSMCs show an alteration in components of the extracellular matrix such as an increase in fibronectin (138) and a decrease in hyaluronan synthesis (85). Insulin increases the production of VSMC PAI-1, a protease inhibitor implicated in preventing fibrinolysis (139).

C. Monocyte/macrophages
Circulating monocytes are important inflammatory cells involved in the immune response. Vessel wall lipid retention stimulates monocytes to differentiate into macrophages in an attempt to phagocytose and remove retained lipid. Because macrophages cannot break down lipid and there is an imbalance between cholesterol influx/efflux, cholesterol remains in the macrophages and these cells are described as "foam cells." Foam cells are deposited in the subendothelial space and the atherosclerotic lesion develops around the lipid-laden macrophages (105).

Insulin and IGF-I receptors are present on circulating monocytes/macrophages (140, 141). Insulin-treated macrophages show classical activation of the insulin signaling pathway. Insulin and IGF-I can activate tyrosine phosphorylation of the ß-subunit of the respective receptors (141). The insulin receptor is tyrosine phosphorylated, leading to activation of IRS-2 and PI (3)K (142). Unlike the classical substrates required for insulin signaling in metabolic tissue, endothelial cells and VSMCs, IRS-1 is undetectable in monocytes/macrophages (141, 143).

Treatment of rat macrophages with insulin increases hexokinase activity, which phosphorylates glucose during glycolysis, and decreases glucose-6-phosphate dehydrogenase, a key enzyme of the pentose phosphate pathway, an alternative pathway to glycolysis (144). Of the glucose transporters, macrophages express GLUT1, GLUT3, and GLUT5, which are distinctly regulated during monocyte differentiation into macrophages (145). However, insulin treatment of mice macrophages has no significant effect on glucose uptake by macrophages (142). Treatment of macrophages with insulin does not increase phagocytosis (144).

Defective insulin signaling is implicated in macrophage foam cell formation (142). Reduced insulin receptor number, decreased insulin receptor/IRS-2 phosphorylation, and downstream signaling occurs in macrophages from obese, insulin-resistant mice (142). To support these findings, reduced insulin receptors on monocytes have also been documented in human monocytes from obese subjects (146). Insulin infusion by the clamp technique, while maintaining normal plasma glucose, reduces monocyte insulin receptors in a dose- and time-dependent manner (147). In addition, defective insulin signaling in terms of reduced receptor tyrosine kinase activity is observed in monocytes from nonobese, normoglycemic subjects with insulin resistance (148).

Macrophages from obese, insulin-resistant mice show an up-regulation of CD36, the macrophage receptor for oxLDL, compared with macrophages from wild-type mice (142). Insulin-treated rat macrophages from nonobese mice show an increase in CD36 receptor and increased binding to oxLDL (142). Macrophage CD36- and ApoE-deficient mice show reduced vascular disease compared with ApoE knockout controls, and thus CD36 is implicated in atherosclerosis (149). Macrophages lacking the insulin receptor obtained from insulin receptor knockout mice show an increase in CD36 protein when compared with macrophages from mice that express the insulin receptor (142). Treatment of normal mice macrophages with different PI (3)K inhibitors, wortmannin or LY294002, in the absence of insulin increases CD36 receptor expression and binding to oxLDL, indicating that defective insulin signaling, as would occur in insulin resistance, regulates macrophage CD36 expression (142). Monocytes isolated from patients with diabetes also show an increase in CD36 expression, and this may be due to defective insulin signaling (150).

Macrophages from mice with alloxan-induced diabetes produce more IL-6, TNF-, and reactive oxygen species compared with macrophages from nondiabetic control mice (151). Macrophage apoptosis in atherosclerotic lesions may contribute to further monocyte recruitment by the release of cytokines and may thus aggravate the development of the vascular lesion and play a part in plaque rupture (152, 153, 154). Insulin treatment of human macrophages reduced apoptosis induced by incubating macrophages in serum-free medium, by increasing the expression of the antiapoptosis gene B-cell lymphoma-X (Bcl-X) (155). Insulin-induced expression of macrophage Bcl-X is inhibited by wortmannin a PI (3)K inhibitor but not by the MAPK inhibitor PD98059 (155). These studies suggest that under insulin resistance conditions the protective effect of insulin to reduce macrophage apoptosis may be lost because the PI (3)K pathway is blunted under these conditions.

D. T lymphocytes
Like monocytes, T lymphocytes adhere and infiltrate the vascular endothelium where they are immunologically active (156, 157). Both CD4+ (T-helper cells) and CD8+ (cytotoxic T cells) cells have been found in human atherosclerotic lesions (41, 42). T-helper 1 cells secrete cytokines such as interferon-, IL-2, and TNF- and -ß, which promote macrophage activation. T-helper 2 cells secrete IL-4, IL-5, and IL-10, which are also found in atherosclerotic plaques. Markers of atherosclerosis and insulin resistance such as increased serum FFA decrease normal T lymphocyte calcium signaling both in vivo and in vitro (158). C-peptide, a product of proinsulin that is increased in insulin-resistant subjects, colocalizes with CD4+ T lymphocytes in atherosclerotic lesions from patients with diabetes and acts as a chemotactic stimulus for T lymphocytes to adhere and penetrate the vessel wall (159).

Of all the cells involved in atherosclerosis, insulin signaling in T lymphocytes has received the least attention. Unlike monocytes, T lymphocytes do not have insulin receptors in the circulation; however, T lymphocytes have the unusual ability to express insulin receptors after presentation of an antigen in vivo and an antigen or mitogen in vitro (160). Once activated, T lymphocytes demonstrate classical insulin signaling such as increased phosphorylation of IRS-1 (161) and downstream metabolic effects such as increased glucose uptake mediated via PI (3)K (162). Stimulation of the insulin receptor on T lymphocytes increases the cytotoxic effects, allows for differentiation of the cells, and maintains the lymphocyte in the activated state after presented with a mitogen (lectin) or antigen. The insulin receptor allows the activated lymphocytes to accommodate extra energy requirements (162, 163).

Plasma insulin levels in vivo have an inverse relationship with the number of insulin receptors on T cells in vitro after the presentation of an antigen (164). The number of insulin receptors on T lymphocytes stimulated by an antigen in vitro is reduced after removal from patients with obesity, and there are even fewer antigen-stimulated insulin receptors when the T cells are from patients with type 2 diabetes (165). In subjects without diabetes, an acute increase in plasma insulin independent of plasma glucose decreases the number of binding sites for insulin on T lymphocytes after presentation of an antigen in vitro (160). Insulin treatment of activated T lymphocytes from normal subjects leads to an increase in the expression of IL-2 mRNA (161).

IGFRs are present on T lymphocytes in the circulation (166). IGF-I treatment of T lymphocytes decreases the expression of interferon- receptor 2 (167). IL-10 has antiinflammatory actions by decreasing T-helper 1-dependent inflammatory effects. IGF-I stimulates the production and mRNA expression of IL-10 in purified T lymphocytes (168). It is unclear which downstream insulin signaling pathways are involved in the effects of IGF-I on modulating the secretion of cytokines from T lymphocytes.

	VIII. Abnormal Signaling in Insulin Resistance in Vascular Tissues

Top Abstract I. Introduction II. Pathology of Atherosclerosis III. Biochemical and Cellular... IV. Metabolic Pathophysiology of... V. Inflammation, Insulin... VI. Normal Insulin Receptor... VII. Insulin Signaling and... VIII. Abnormal Signaling in... IX. Conclusions, Implications,... References

 
Insulin resistance may be due to defect(s) at some point before insulin binding to its receptor, an insulin receptor defect, and/or defects in downstream signaling components. Insulin receptor defects in specific tissues do not necessarily confer systemic insulin resistance. Pre-insulin receptor faults generally result from genetic mutations in the insulin receptor gene (rare) or alterations in delivery of insulin to its receptors giving rise to reduced insulin effectiveness. Defects in the insulin receptor that may contribute to insulin resistance include defects in receptor structure, number, binding affinity, and/or signaling capacity. It could be expected that an increased number of hybrid receptors (IGF-I/ insulin receptor) would reduce insulin sensitivity with these receptors preferentially binding IGF-I under physiological conditions; however, to date there is conflicting evidence regarding receptor structure, isoform expression, and binding affinity contributing to insulin resistance in type 2 diabetes in humans (62, 169).

Insulin resistance results in decreased FFA uptake and/or increased FFA levels in adipocytes and in the circulation. The basis for this change in fat cell metabolism leading to increased intracellular hydrolysis of triglycerides is not known. Insulin resistance often accompanies visceral obesity and elevated levels of the atherogenic factor PAI-1 (170). High circulating FFA levels enhance glucose output from the liver and reduce glucose disposal in skeletal muscle, thereby contributing to insulin resistance. To date there is no clear evidence to link any candidate regulators of fatty acid metabolism with insulin resistance. Increased FFAs stimulate the assembly and secretion of very low-density lipoprotein (VLDL) from the liver. Increased plasma levels of VLDL contribute to an increased accumulation of VLDL in the blood vessel wall in atherosclerosis. Indeed, the higher plasma levels of VLDL can result in higher levels of small, dense LDL and consequently deliver greater amounts of cholesterol to the vessel wall (171), where it becomes bound to proteoglycans within the extracellular matrix and can thereby contribute to plaque formation (172).

There has been considerable work on the direct actions of insulin on blood vessels and cells of the vasculature. The rationale for these studies varies from a view that these agents may be pro- or antiatherogenic. The concept of insulin resistance provides a particular perspective on these actions. If insulin resistance is associated with accelerated processes of atherosclerosis, then actions of insulin that are antiatherogenic are attenuated, insulin actions that are proatherogenic are exaggerated, or both. Thus, what are the direct actions of insulin in the vasculature, and how might insulin resistance be manifest?

Considerable evidence exists implicating vascular endothelium as a physiological target of insulin and, consequently, a potential link between insulin resistance and atherosclerosis. Endothelial dysfunction is one of the earliest detectable signs in insulin resistance, occurring even before the development of clinical manifestations. Insulin, a vasodilator, increases endothelial NO production and is regulated via PI (3)K-dependent/Akt insulin receptor signaling (91). Insulin normally stimulates the net production of NO via eNOS/tetrahydrobiopterin (BH4) activity. Impairment of NO production leads to insulin resistance such as that seen in eNOS knockout mice (100) and humans treated with an eNOS antagonist L-nitro monomethyl arginine (173), highlighting the involvement of eNOS and endothelial cells in insulin resistance and the potential to be proatherogenic if eNOS levels are reduced. Impairment of NO production has been demonstrated to be via a number of pathways including altered phosphorylation of eNOS, depleted BH4 availability, and impaired endothelin-1 signaling via ET_B (174). It is not evident whether a reduction in NO necessarily confers insulin resistance because not all disease states that have decreased endothelial NO have associated insulin resistance. Reduced NO production impacts not only on endothelial cells but also on VSMCs, the major constituent of the vessel wall responsible for vascular integrity and tone. In insulin resistance, VSMCs have an impaired responsiveness to NO, resulting in increased contraction that can result in an imbalance in vascular tone and may impact on insulin-mediated delivery of glucose to muscle in the insulin-resistant state (96).

Although the PI (3)K-dependent insulin signaling pathway is impaired in virtually all states of insulin resistance, the mitogenic MAPK pathway in endothelial and VSMCs remains intact and responds normally to insulin, and its associated cell effects may actually be enhanced rather than attenuated (107, 175, 176). Preferential signaling along this pathway may contribute to the progression of atherosclerosis with a concomitant increase in VSMC migration in the expression of cell adhesion molecules (VCAM-1, E-selectin) and cell interactions between vascular cells and macrophage/monocytes (107). VSMCs are also stimulated to increase production of PAI-1, resulting in reduced fibrinolysis and increased vascular occlusion and increased prenylation of GTPases Ras and Rho, leading to an enhanced mitogenic response of these cells to growth factors including PDGF (120). Macrophages also demonstrate alterations in their signaling pathways in insulin resistance. Macrophages from obese (ob/ob) mice are insulin resistant and display a posttranscriptional increase in CD36, a key molecule in the recognition of modified LDL, as a direct result of decreased insulin signaling (142). The elevated level of CD36 is a result of decreased catabolism, indicating a defect in receptor trafficking in macrophages, and results in increased binding, uptake, and degradation of LDL that may contribute to the development of atherosclerosis in the insulin-resistant state.

	IX. Conclusions, Implications, and Speculations

Top Abstract I. Introduction II. Pathology of Atherosclerosis III. Biochemical and Cellular... IV. Metabolic Pathophysiology of... V. Inflammation, Insulin... VI. Normal Insulin Receptor... VII. Insulin Signaling and... VIII. Abnormal Signaling in... IX. Conclusions, Implications,... References

 
It is clear from the above analysis that the exact molecular cause of insulin resistance is presently unknown. Several observations allow us to speculate on its origins. The key factors in insulin resistance are the presence of obesity and a genetic component. Increasing obesity is associated with increasing insulin resistance, but there is an overlay of genetic susceptibility. Thus, there exist lean people with severe insulin resistance and obese people without insulin resistance. The genetic component appears to have a subtle molecular manifestation and not an overt change in receptor structure or function. Numerous steps have been identified in the process of insulin signaling that convert insulin binding to increased glucose uptake in traditional insulin-sensitive tissues. Metabolic factors associated with obesity, such as FFA, can modulate insulin signaling pathways, so we speculate that there are molecular processes in the insulin signaling cascade that are susceptible to inhibition or activation by metabolic factors associated with obesity, and thus the spectrum of responses results from the interactions between these factors to yield a spectrum of insulin-resistant states.

Insulin resistance is associated with accelerated atherosclerosis, and a major question is whether or not insulin resistance occurs in cardiovascular tissues and whether this is the driving force for accelerated cardiovascular disease. From the viewpoint of antiatherosclerotic drug therapy, the recent discovery and introduction of the agents being chemically thiazolidinediones and pharmacologically peroxisome proliferator-activated receptor- ligands, which improve insulin resistance, along with increasing use of metformin, which also improves insulin sensitivity, provides a very useful opportunity to address the burden of disease associated with insulin resistance. In addition, the last two decades of vascular biology research have yielded much information on the biochemical and cell biology factors involved in the formation, progression, and rupture of atherosclerotic plaques, and it is hoped that this will lead to the discovery of agents that directly target these mechanisms in the vessel wall (177). Thus, greater understanding of the role of lifestyle interventions and their implementation and compliance coupled with new therapeutic strategies for targeting insulin resistance and the vessel wall should provide the pathways to alleviate the huge burden of cardiovascular disease that is confronting the world at present.

	Acknowledgments

 
The authors thank Stephen Twigg, M.D., Ph.D. (University of Sydney, Department of Medicine) for constructively critiquing this review.

	Footnotes

 
The laboratory has received financial support over the last several years from the National Health and Medical Research Council of Australia, Diabetes Australia Research Trust, Eli Lilly Endocrinology Research Awards, GlaxoSmithKline (Australia), Monash University, Department of Medicine, and the Baker Heart Research Institute, Division of Vascular Biology. Postgraduate students are funded by Australian Postgraduate Awards and the Biomedical (Dora Lush) Postgraduate Research Scholarship from the National Health and Medical Research Council of Australia.

First Published Online February 21, 2006

Abbreviations: eNOS, Endothelial NO synthase; FFA, free fatty acid; GAG, glycosaminoglycan; ICAM, intercellular adhesion molecule; IGFR, IGF receptor; iNOS, inducible NO synthase; IRS, insulin-receptor substrate; LDL, low-density lipoprotein; MMP, matrix metalloproteinase; NO, nitric oxide; oxLDL, oxidized LDL; PAI, plasminogen activator inhibitor; PDGF, platelet-derived growth factor; PI (3)K, phosphatidylinositol-3-kinase; PKC, protein kinase C; PKG, protein kinase G; SMC, smooth muscle cell; VCAM, vascular adhesion molecule; VLDL, very low-density lipoprotein; VSMC, vascular SMC.

	References

Top Abstract I. Introduction II. Pathology of Atherosclerosis III. Biochemical and Cellular... IV. Metabolic Pathophysiology of... V. Inflammation, Insulin... VI. Normal Insulin Receptor... VII. Insulin Signaling and... VIII. Abnormal Signaling in... IX. Conclusions, Implications,... References

 

1. Banting F, Best C 1922 The internal secretion of the pancreas. J Lab Clin Med 7:256–271
2. Yalow RS, Berson SA 1959 Assay of plasma insulin in human subjects by immunological methods. Nature 184(Suppl 21):1648–1649
3. Himsworth H 1936 Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. Lancet i:127–130
4. Bornstein J, Lawrence RD 1951 Two types of diabetes mellitus, with and without available plasma insulin. Br Med J 7:732
5. Colman PG, Thomas DW, Zimmet PZ, Welborn TA, Garcia-Webb P, Moore MP 1999 New classification and criteria for diagnosis of diabetes mellitus. Position Statement from the Australian Diabetes Society, New Zealand Society for the Study of Diabetes, Royal College of Pathologists of Australasia and Australasian Association of Clinical Biochemists. Med J Aust 170:375–378[Medline]
6. American Diabetes Association 2004 Diagnosis and classification of diabetes mellitus. Diabetes Care 27(Suppl 1):S5–S10
7. Hollenbeck C, Reaven GM 1987 Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab 64:1169–1173[Abstract/Free Full Text]
8. Zimmet P, Whitehouse S, Alford F, Chisholm D 1978 The relationship of insulin response to a glucose stimulus over a wide range of glucose tolerance. Diabetologia 15:23–27[CrossRef][Medline]
9. Alberti KG, Zimmet P, Shaw J 2005 The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062[CrossRef][Medline]
10. Reaven GM 1988 Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607[Abstract]
11. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K 2004 Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164:1066–1076[Abstract/Free Full Text]
12. Cefalu WT 2001 Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood) 226:13–26[Abstract/Free Full Text]
13. Watkins LL, Sherwood A, Feinglos M, Hinderliter A, Babyak M, Gullette E, Waugh R, Blumenthal JA 2003 Effects of exercise and weight loss on cardiac risk factors associated with syndrome X. Arch Intern Med 163:1889–1895[Abstract/Free Full Text]
14. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D’Armiento M, D’Andrea F, Giugliano D 2004 Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292:1440–1446[Abstract/Free Full Text]
15. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT 2004 The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 256:1–14[CrossRef][Medline]
16. UK Prospective Diabetes Study (UKPDS) Group 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865[CrossRef][Medline]
17. Yki-Jarvinen H 2004 Thiazolidinediones. N Engl J Med 351:1106–1118[Free Full Text]
18. Evans RM, Barish GD, Wang YX 2004 PPARs and the complex journey to obesity. Nat Med 10:355–361[CrossRef][Medline]
19. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK 2000 Peroxisome proliferator-activated receptor ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523–531[Medline]
20. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE 2001 Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21:365–371[Abstract/Free Full Text]
21. Rangwala SM, Lazar MA 2004 Peroxisome proliferator-activated receptor in diabetes and metabolism. Trends Pharmacol Sci 25:331–336[CrossRef][Medline]
22. McNeill AM, Rosamond WD, Girman CJ, Heiss G, Golden SH, Duncan BB, East HE, Ballantyne C 2004 Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol 94:1249–1254[CrossRef][Medline]
23. Silva JA, Escobar A, Collins TJ, Ramee SR, White CJ 1995 Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation 92:1731–1736[Abstract/Free Full Text]
24. O’Brien ER, Alpers CE, Stewart DK, Ferguson M, Tran N, Gordon D, Benditt EP, Hinohara T, Simpson JB, Schwartz SM 1993 Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy. Circ Res 73:223–231[Abstract/Free Full Text]
25. Ross R 1993 The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801–809[CrossRef][Medline]
26. McGill Jr HC, McMahan CA, Zieske AW, Sloop GD, Walcott JV, Troxclair DA, Malcom GT, Tracy RE, Oalmann MC, Strong JP 2000 Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 20:1998–2004[Abstract/Free Full Text]
27. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull Jr W, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW 1994 A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 89:2462–2478[Abstract/Free Full Text]
28. Muir R 1992 Cardiovascular system. In: MacSween RNM, Whaley K, eds. Muir’s textbook of pathology. Chap. 12. 13th ed. London: Hodder and Stoughton Ltd.
29. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ 1995 Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91:2488–2496[Abstract/Free Full Text]
30. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL 1994 High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 93:2393–2402[Medline]
31. Ross R, Glomset JA 1976 The pathogenesis of atherosclerosis (second of two parts). N Engl J Med 295:420–425[Medline]
32. Ross R, Glomset JA 1976 The pathogenesis of atherosclerosis (first of two parts). N Engl J Med 295:369–377[Medline]
33. Ross R 1999 Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126[Free Full Text]
34. Williams KJ, Tabas I 1995 The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15:551–561[Free Full Text]
35. Williams KJ, Tabas I 1998 The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 9:471–474[CrossRef][Medline]
36. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, Boren J 2002 Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417:750–754[CrossRef][Medline]
37. Witztum JL 1994 The oxidation hypothesis of atherosclerosis. Lancet 344:793–795[CrossRef][Medline]
38. Griendling KK, Alexander RW 1997 Oxidative stress and cardiovascular disease. Circulation 96:3264–3265[Medline]
39. Blankenberg S, Barbaux S, Tiret L 2003 Adhesion molecules and atherosclerosis. Atherosclerosis 170:191–203[CrossRef][Medline]
40. Cuff CA, Kothapalli D, Azonobi I, Chun S, Zhang Y, Belkin R, Yeh C, Secreto A, Assoian RK, Rader DJ, Pure E 2001 The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest 108:1031–1040[CrossRef][Medline]
41. Hansson GK, Jonasson L, Lojsthed B, Stemme S, Kocher O, Gabbiani G 1988 Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis 72:135–141[CrossRef][Medline]
42. Emeson EE, Robertson Jr AL 1988 T lymphocytes in aortic and coronary intimas. Their potential role in atherogenesis. Am J Pathol 130:369–376[Abstract]
43. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL 1989 Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 86:1372–1376[Abstract/Free Full Text]
44. Rosenfeld ME, Palinski W, Yla-Herttuala S, Butler S, Witztum JL 1990 Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 10:336–349[Abstract/Free Full Text]
45. Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL 1990 Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10:325–335[Abstract/Free Full Text]
46. Kahn R, Buse J, Ferrannini E, Stern M 2005 The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28:2289–2304[Abstract/Free Full Text]
47. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L 2001 Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689[Abstract/Free Full Text]
48. Randle PJ, Garland PB, Hales CN, Newsholme EA 1963 The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785–789[Medline]
49. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, Inzucchi S, Dresner A, Rothman DL, Shulman GI 1999 Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341:240–246[Abstract/Free Full Text]
50. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, Uejima H, Tanaka H, Maruyama M, Satoh R, Okubo S, Kizawa H, Komatsu H, Matsumura F, Noguchi Y, Shinohara T, Hinuma S, Fujisawa Y, Fujino M 2003 Free fatty acids regulate insulin secretion from pancreatic ß cells through GPR40. Nature 422:173–176[CrossRef][Medline]
51. Boden G, Chen X 1999 Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. Diabetes 48:577–583[Abstract]
52. Milburn Jr JL, Hirose H, Lee YH, Nagasawa Y, Ogawa A, Ohneda M, BeltrandelRio H, Newgard CB, Johnson JH, Unger RH 1995 Pancreatic ß-cells in obesity. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. J Biol Chem 270:1295–1299[Abstract/Free Full Text]
53. Segall L, Lameloise N, Assimacopoulos-Jeannet F, Roche E, Corkey P, Thumelin S, Corkey BE, Prentki M 1999 Lipid rather than glucose metabolism is implicated in altered insulin secretion caused by oleate in INS-1 cells. Am J Physiol 277:E521–E528
54. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH 1994 ß-Cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-ß-cell relationships. Proc Natl Acad Sci USA 91:10878–10882[Abstract/Free Full Text]
55. Pittas AG, Joseph NA, Greenberg AS 2004 Adipocytokines and insulin resistance. J Clin Endocrinol Metab 89:447–452[Free Full Text]
56. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F 1995 Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269:540–543[Abstract/Free Full Text]
57. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE 2005 Local and systemic insulin resistance resulting from hepatic activation of IKK-ß and NF-B. Nat Med 11:183–190[CrossRef][Medline]
58. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I 2004 Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752–1761[CrossRef][Medline]
59. Glass CK, Witztum JL 2001 Atherosclerosis. The road ahead. Cell 104:503–516[CrossRef][Medline]
60. Libby P 2002 Inflammation in atherosclerosis. Nature 420:868–874[CrossRef][Medline]
61. Grassot J, Mouchiroud G, Perriere G 2003 RTKdb: database of receptor tyrosine kinase. Nucleic Acids Res 31:353–358[Abstract/Free Full Text]
62. Sesti G, Federici M, Lauro D, Sbraccia P, Lauro R 2001 Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. Diabetes Metab Res Rev 17:363–373[CrossRef][Medline]
63. Federici M, Porzio O, Zucaro L, Fusco A, Borboni P, Lauro D, Sesti G 1997 Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues. Mol Cell Endocrinol 129:121–126[CrossRef][Medline]
64. Chisalita SI, Arnqvist HJ 2004 Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells. Am J Physiol Endocrinol Metab 286:E896–E901
65. Pessin JE, Saltiel AR 2000 Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106:165–169[Medline]
66. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC, Ramachandran C, Gresser MJ, Tremblay ML, Kennedy BP 1999 Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283:1544–1548[Abstract/Free Full Text]
67. White MF 1998 The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 182:3–11[CrossRef][Medline]
68. Saltiel AR, Kahn CR 2001 Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799–806[CrossRef][Medline]
69. Myers Jr MG, Wang LM, Sun XJ, Zhang Y, Yenush L, Schlessinger J, Pierce JH, White MF 1994 Role of IRS-1-GRB-2 complexes in insulin signaling. Mol Cell Biol 14:3577–3587[Abstract/Free Full Text]
70. Skolnik EY, Batzer A, Li N, Lee CH, Lowenstein E, Mohammadi M, Margolis B, Schlessinger J 1993 The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 260:1953–1955[Abstract/Free Full Text]
71. Sun XJ, Pons S, Asano T, Myers Jr MG, Glasheen E, White MF 1996 The Fyn tyrosine kinase binds Irs-1 and forms a distinct signaling complex during insulin stimulation. J Biol Chem 271:10583–10587[Abstract/Free Full Text]
72. Ruderman NB, Kapeller R, White MF, Cantley LC 1990 Activation of phosphatidylinositol 3-kinase by insulin. Proc Natl Acad Sci USA 87:1411–1415[Abstract/Free Full Text]
73. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, Holmes AB, McCormick F, Hawkins PT 1997 Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277:567–570[Abstract/Free Full Text]
74. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw 3rd EB, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ 2001 Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBß). Science 292:1728–1731[Abstract/Free Full Text]
75. Du K, Herzig S, Kulkarni RN, Montminy M 2003 TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300:1574–1577[Abstract/Free Full Text]
76. Bailyes EM, Nave BT, Soos MA, Orr SR, Hayward AC, Siddle K 1997 Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J 327(Pt 1):209–215
77. Hayashi K, Shibata K, Morita T, Iwasaki K, Watanabe M, Sobue K 2004 Insulin receptor substrate-1/SHP-2 interaction, a phenotype-dependent switching machinery of insulin-like growth factor-I signaling in vascular smooth muscle cells. J Biol Chem 279:40807–40818[Abstract/Free Full Text]
78. Valentinis B, Reiss K, Baserga R 1998 Insulin-like growth factor-I-mediated survival from anoikis: role of cell aggregation and focal adhesion kinase. J Cell Physiol 176:648–657[CrossRef][Medline]
79. Boney CM, Smith RM, Gruppuso PA 1998 Modulation of insulin-like growth factor I mitogenic signaling in 3T3–L1 preadipocyte differentiation. Endocrinology 139:1638–1644[Abstract/Free Full Text]
80. Cercek B, Fishbein MC, Forrester JS, Helfant RH, Fagin JA 1990 Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation. Circ Res 66:1755–1760[Abstract/Free Full Text]
81. Miano JM, Vlasic N, Tota RR, Stemerman MB 1993 Smooth muscle cell immediate-early gene and growth factor activation follows vascular injury. A putative in vivo mechanism for autocrine growth. Arterioscler Thromb 13:211–219[Abstract/Free Full Text]
82. Prior JO, Quinones MJ, Hernandez-Pampaloni M, Facta AD, Schindler TH, Sayre JW, Hsueh WA, Schelbert HR 2005 Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 111:2291–2298[Abstract/Free Full Text]
83. Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE 2000 A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes 49:2094–2101[Abstract/Free Full Text]
84. de la Motte CA, Hascall VC, Drazba J, Bandyopadhyay SK, Strong SA 2003 Mononuclear leukocytes bind to specific hyaluronan structures on colon mucosal smooth muscle cells treated with polyinosinic acid:polycytidylic acid: inter--trypsin inhibitor is crucial to structure and function. Am J Pathol 163:121–133[Abstract/Free Full Text]
85. Erikstrup C, Pedersen LM, Heickendorff L, Ledet T, Rasmussen LM 2001 Production of hyaluronan and chondroitin sulphate proteoglycans from human arterial smooth muscle—the effect of glucose, insulin, IGF-I or growth hormone. Eur J Endocrinol 145:193–198[Abstract]
86. Vecchione C, Aretini A, Maffei A, Marino G, Selvetella G, Poulet R, Trimarco V, Frati G, Lembo G 2003 Cooperation between insulin and leptin in the modulation of vascular tone. Hypertension 42:166–170[Abstract/Free Full Text]
87. Bar RS, Hoak JC, Peacock ML 1978 Insulin receptors in human endothelial cells: identification and characterization. J Clin Endocrinol Metab 47:699–702[Abstract/Free Full Text]
88. Bar RS, Peacock ML, Spanheimer RG, Veenstra R, Hoak JC 1980 Differential binding of insulin to human arterial and venous endothelial cells in primary culture. Diabetes 29:991–995[Abstract]
89. King GL, Buzney SM, Kahn CR, Hetu N, Buchwald S, Macdonald SG, Rand LI 1983 Differential responsiveness to insulin of endothelial and support cells from micro- and macrovessels. J Clin Invest 71:974–979[Medline]
90. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL 2000 Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 101:676–681[Abstract/Free Full Text]
91. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ 2000 Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101:1539–1545[Abstract/Free Full Text]
92. Andreozzi F, Laratta E, Sciacqua A, Perticone F, Sesti G 2004 Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ Res 94:1211–1218[Abstract/Free Full Text]
93. Garg UC, Hassid A 1989 Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83:1774–1777[Medline]
94. Wu HY, Jeng YY, Yue CJ, Chyu KY, Hsueh WA, Chan TM 1994 Endothelial-dependent vascular effects of insulin and insulin-like growth factor I in the perfused rat mesenteric artery and aortic ring. Diabetes 43:1027–1032[Abstract]
95. Zeng G, Quon MJ 1996 Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 98:894–988[Medline]
96. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD 1996 Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97:2601–2610[Medline]
97. Quinones MJ, Hernandez-Pampaloni M, Schelbert H, Bulnes-Enriquez I, Jimenez X, Hernandez G, De La Rosa R, Chon Y, Yang H, Nicholas SB, Modilevsky T, Yu K, Van Herle K, Castellani LW, Elashoff R, Hsueh WA 2004 Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med 140:700–708[Abstract/Free Full Text]
98. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, Matthaei S, Rett K, Haring HU 2000 Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101:1780–1784[Abstract/Free Full Text]
99. Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki YY, Bursell S, Yanagisawa M, King GL, Kahn CR 2003 The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest 111:1373–1380[CrossRef][Medline]
100. Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD 2000 Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 49:684–687[Abstract]
101. Fulton D, Harris MB, Kemp BE, Venema RC, Marrero MB, Stepp DW 2004 Insulin resistance does not diminish eNOS expression, phosphorylation, or binding to HSP-90. Am J Physiol Heart Circ Physiol 287:H2384–H2393
102. Hsueh WA, Lyon CJ, Quinones MJ 2004 Insulin resistance and the endothelium. Am J Med 117:109–117[CrossRef][Medline]
103. Loscalzo J 1992 Antiplatelet and antithrombotic effects of organic nitrates. Am J Cardiol 70:18B–22B
104. Radomski MW, Moncada S 1993 The biological and pharmacological role of nitric oxide in platelet function. Adv Exp Med Biol 344:251–264[Medline]
105. Ross R 1995 Cell biology of atherosclerosis. Annu Rev Rhysiol 57:791–804
106. Liu W, Liu Y, Lowe Jr WL 2001 The role of phosphatidylinositol 3-kinase and the mitogen-activated protein kinases in insulin-like growth factor-I-mediated effects in vascular endothelial cells. Endocrinology 142:1710–1719[Abstract/Free Full Text]
107. Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ, Draznin B 2002 Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 277:1794–1799[Abstract/Free Full Text]
108. Hascall VC, Majors AK, De La Motte CA, Evanko SP, Wang A, Drazba JA, Strong SA, Wight TN 2004 Intracellular hyaluronan: a new frontier for inflammation? Biochim Biophys Acta 1673:3–12[Medline]
109. Chajara A, Raoudi M, Delpech B, Leroy M, Basuyau JP, Levesque H 2000 Increased hyaluronan and hyaluronidase production and hyaluronan degradation in injured aorta of insulin-resistant rats. Arterioscler Thromb Vasc Biol 20:1480–1487[Abstract/Free Full Text]
110. Scotland R, Vallance P, Ahluwalia A 1999 Endothelin alters the reactivity of vasa vasorum: mechanisms and implications for conduit vessel physiology and pathophysiology. Br J Pharmacol 128:1229–1234[CrossRef][Medline]
111. Filep JG, Sirois MG, Foldes-Filep E, Rousseau A, Plante GE, Fournier A, Yano M, Sirois P 1993 Enhancement by endothelin-1 of microvascular permeability via the activation of ETA receptors. Br J Pharmacol 109:880–886[Medline]
112. Bobik A, Grooms A, Millar JA, Mitchell A, Grinpukel S 1990 Growth factor activity of endothelin on vascular smooth muscle. Am J Physiol 258:C408–C415
113. Stankova J, Rola-Pleszczynski M, D’Orleans-Juste P 1995 Endothelin 1 and thrombin synergistically stimulate IL-6 mRNA expression and protein production in human umbilical vein endothelial cells. J Cardiovasc Pharmacol 26(Suppl 3):S505–S507
114. McMillen MA, Huribal M, Cunningham ME, Kumar R, Sumpio BE 1995 Endothelin-1 increases intracellular calcium in human monocytes and causes production of interleukin-6. Crit Care Med 23:34–40[CrossRef][Medline]
115. Liu S, Premont RT, Kontos CD, Huang J, Rockey DC 2003 Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein ß subunit signaling to protein jinase B/Akt. J Biol Chem 278:49929–49935[Abstract/Free Full Text]
116. Hu RM, Levin ER, Pedram A, Frank HJ 1993 Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes 42:351–358[Abstract]
117. Bornfeldt KE, Gidlof RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ 1991 Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34:307–313[CrossRef][Medline]
118. Banskota NK, Taub R, Zellner K, Olsen P, King GL 1989 Characterization of induction of protooncogene c-myc and cellular growth in human vascular smooth muscle cells by insulin and IGF-I. Diabetes 38:123–129[Abstract]
119. Jialal I, Crettaz M, Hachiya HL, Kahn CR, Moses AC, Buzney SM, King GL 1985 Characterization of the receptors for insulin and the insulin-like growth factors on micro- and macrovascular tissues. Endocrinology 117:1222–1229[Abstract/Free Full Text]
120. Wang CC, Gurevich I, Draznin B 2003 Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes 52:2562–2569[Abstract/Free Full Text]
121. Imai Y, Clemmons DR 1999 Roles of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in stimulation of vascular smooth muscle cell migration and deoxyriboncleic acid synthesis by insulin-like growth factor-I. Endocrinology 140:4228–4235[Abstract/Free Full Text]
122. Xi XP, Graf K, Goetze S, Hsueh WA, Law RE 1997 Inhibition of MAP kinase blocks insulin-mediated DNA synthesis and transcriptional activation of c-fos by Elk-1 in vascular smooth muscle cells. FEBS Lett 417:283–286[CrossRef][Medline]
123. Banskota NK, Taub R, Zellner K, King GL 1989 Insulin, insulin-like growth factor I and platelet-derived growth factor interact additively in the induction of the protooncogene c-myc and cellular proliferation in cultured bovine aortic smooth muscle cells. Mol Endocrinol 3:1183–1190[Abstract/Free Full Text]
124. Anderson PW, Zhang XY, Tian J, Correale JD, Xi XP, Yang D, Graf K, Law RE, Hsueh WA 1996 Insulin and angiotensin II are additive in stimulating TGF-ß1 and matrix mRNAs in mesangial cells. Kidney Int 50:745–753[Medline]
125. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP 1997 Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100:2158–2169[Medline]
126. Kaiser N, Tur-Sinai A, Hasin M, Cerasi E 1985 Binding, degradation, and biological activity of insulin in vascular smooth muscle cells. Am J Physiol 249:E292–E298
127. Kobayashi T, Kamata K 2002 Short-term insulin treatment and aortic expressions of IGF-1 receptor and VEGF mRNA in diabetic rats. Am J Physiol Heart Circ Physiol 283:H1761–H1768
128. Bornfeldt KE, Skottner A, Arnqvist HJ 1992 In-vivo regulation of messenger RNA encoding insulin-like growth factor-I (IGF-I) and its receptor by diabetes, insulin and IGF-I in rat muscle. J Endocrinol 135:203–211[Abstract/Free Full Text]
129. Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC 1996 Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 78:225–230[Abstract/Free Full Text]
130. Brown C, Pan X, Hassid A 1999 Nitric oxide and C-type atrial natriuretic peptide stimulate primary aortic smooth muscle cell migration via a cGMP-dependent mechanism: relationship to microfilament dissociation and altered cell morphology. Circ Res 84:655–667[Abstract/Free Full Text]
131. Hassid A, Arabshahi H, Bourcier T, Dhaunsi GS, Matthews C 1994 Nitric oxide selectively amplifies FGF-2-induced mitogenesis in primary rat aortic smooth muscle cells. Am J Physiol 267:H1040–H1048
132. Dhaunsi GS, Hassid A 1996 Atrial and C-type natriuretic peptides amplify growth factor activity in primary aortic smooth muscle cells. Cardiovasc Res 31:37–47[Medline]
133. Nakaki T, Nakayama M, Kato R 1990 Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells. Eur J Pharmacol 189:347–353[CrossRef][Medline]
134. Cornwell TL, Lincoln TM 1989 Regulation of intracellular Ca²⁺ levels in cultured vascular smooth muscle cells. Reduction of Ca²⁺ by atriopeptin and 8-bromo-cyclic GMP is mediated by cyclic GMP-dependent protein kinase. J Biol Chem 264:1146–1155[Abstract/Free Full Text]
135. Dixit M, Zhuang D, Ceacareanu B, Hassid A 2003 Treatment with insulin uncovers the motogenic capacity of nitric oxide in aortic smooth muscle cells: dependence on Gab1 and Gab1-SHP2 association. Circ Res 93:e113–e123
136. Komalavilas P, Shah PK, Jo H, Lincoln TM 1999 Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells. J Biol Chem 274:34301–34309[Abstract/Free Full Text]
137. Kubota T, Kubota N, Moroi M, Terauchi Y, Kobayashi T, Kamata K, Suzuki R, Tobe K, Namiki A, Aizawa S, Nagai R, Kadowaki T, Yamaguchi T 2003 Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation 107:3073–3080[Abstract/Free Full Text]
138. Tamaroglio TA, Lo CS 1994 Regulation of fibronectin by insulin-like growth factor-I in cultured rat thoracic aortic smooth muscle cells and glomerular mesangial cells. Exp Cell Res 215:338–346[CrossRef][Medline]
139. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D 1986 Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 35:250–253[CrossRef][Medline]
140. Bar RS, Kahn CR, Koren HS 1977 Insulin inhibition of antibody-dependent cytoxicity and insulin receptors in macrophages. Nature 265:632–635[CrossRef][Medline]
141. Zoppini G, Galante P, Zardini M, Muggeo M 1994 Phosphotyrosine protein profiles in monocytes after insulin and IGF-1 stimulation. Eur J Clin Invest 24:275–278[Medline]
142. Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, Accili D, Tall AR 2004 Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest 113:764–773[CrossRef][Medline]
143. Welham MJ, Bone H, Levings M, Learmonth L, Wang LM, Leslie KB, Pierce JH, Schrader JW 1997 Insulin receptor substrate-2 is the major 170-kDa protein phosphorylated on tyrosine in response to cytokines in murine lymphohemopoietic cells. J Biol Chem 272:1377–1381[Abstract/Free Full Text]
144. Rosa LF, Cury Y, Curi R 1992 Effects of insulin, glucocorticoids and thyroid hormones on the activities of key enzymes of glycolysis, glutaminolysis, the pentose-phosphate pathway and the Krebs cycle in rat macrophages. J Endocrinol 135:213–219[Abstract/Free Full Text]
145. Malide D, Davies-Hill TM, Levine M, Simpson IA 1998 Distinct localization of GLUT-1, -3, and -5 in human monocyte-derived macrophages: effects of cell activation. Am J Physiol 274:E516–E526
146. Bar RS, Gorden P, Roth J, Kahn CR, De Meyts P 1976 Fluctuations in the affinity and concentration of insulin receptors on circulating monocytes of obese patients: effects of starvation, refeeding, and dieting. J Clin Invest 58:1123–1135[Medline]
147. Soman VR, DeFronzo RA 1980 Direct evidence for downregulation of insulin receptors by physiologic hyperinsulinemia in man. Diabetes 29:159–163[Abstract]
148. Frittitta L, Grasso G, Munguira ME, Vigneri R, Trischitta V 1993 Insulin receptor tyrosine kinase activity is reduced in monocytes from non-obese normoglycaemic insulin-resistant subjects. Diabetologia 36:1163–1167[CrossRef][Medline]
149. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL 2000 Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105:1049–1056[Medline]
150. Sampson MJ, Davies IR, Braschi S, Ivory K, Hughes DA 2003 Increased expression of a scavenger receptor (CD36) in monocytes from subjects with type 2 diabetes. Atherosclerosis 167:129–134[CrossRef][Medline]
151. Ptak W, Klimek M, Bryniarski K, Ptak M, Majcher P 1998 Macrophage function in alloxan diabetic mice: expression of adhesion molecules, generation of monokines and oxygen and NO radicals. Clin Exp Immunol 114:13–18[CrossRef][Medline]
152. Bjorkerud S, Bjorkerud B 1996 Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol 149:367–380[Abstract]
153. Hegyi L, Hardwick SJ, Mitchinson MJ, Skepper JN 1997 The presence of apoptotic cells in human atherosclerotic lesions. Am J Pathol 150:371–373[Medline]
154. Kockx MM, Herman AG 1998 Apoptosis in atherogenesis: implications for plaque destabilization. Eur Heart J 19 Suppl G:G23–G28
155. Iida KT, Suzuki H, Sone H, Shimano H, Toyoshima H, Yatoh S, Asano T, Okuda Y, Yamada N 2002 Insulin inhibits apoptosis of macrophage cell line, THP-1 cells, via phosphatidylinositol-3-kinase-dependent pathway. Arterioscler Thromb Vasc Biol 22:380–386[Abstract/Free Full Text]
156. Hansson GK, Holm J, Jonasson L 1989 Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 135:169–175[Abstract]
157. Masuyama J, Berman JS, Cruikshank WW, Morimoto C, Center DM 1992 Evidence for recent as well as long term activation of T cells migrating through endothelial cell monolayers in vitro. J Immunol 148:1367–1374[Abstract]
158. Stulnig TM, Berger M, Roden M, Stingl H, Raederstorff D, Waldhausl W 2000 Elevated serum free fatty acid concentrations inhibit T lymphocyte signaling. FASEB J 14:939–947[Abstract/Free Full Text]
159. Walcher D, Aleksic M, Jerg V, Hombach V, Zieske A, Homma S, Strong J, Marx N 2004 C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase. Diabetes 53:1664–1670[Abstract/Free Full Text]
160. Helderman JH 1984 Acute regulation of human lymphocyte insulin receptors. Analysis by the glucose clamp. J Clin Invest 74:1428–1435[Medline]
161. Stentz FB, Kitabchi AE 2004 De novo emergence of growth factor receptors in activated human CD4+ and CD8+ T lymphocytes. Metabolism 53:117–122[CrossRef][Medline]
162. Helderman JH 1981 Role of insulin in the intermediary metabolism of the activated thymic-derived lymphocyte. J Clin Invest 67:1636–1642[Medline]
163. Helderman JH 1983 T cell cooperation for the genesis of B cell insulin receptors. J Immunol 131:644–650[Medline]
164. Helderman JH, Pietri AO, Raskin P 1983 In vitro control of T-lymphocyte insulin receptors by in vivo modulation of insulin. Diabetes 32:712–717[Medline]
165. Helderman JH, Raskin P 1980 The T lymphocyte insulin receptor in diabetes and obesity: an intrinsic binding defect. Diabetes 29:551–557[Medline]
166. Kooijman R, Willems M, De Haas CJ, Rijkers GT, Schuurmans AL, Van Buul-Offers SC, Heijnen CJ, Zegers BJ 1992 Expression of type I insulin-like growth factor receptors on human peripheral blood mononuclear cells. Endocrinology 131:2244–2250[Abstract/Free Full Text]
167. Bernabei P, Bosticardo M, Losana G, Regis G, Di Paola F, De Angelis S, Giovarelli M, Novelli F 2003 IGF-1 down-regulates IFN- R2 chain surface expression and desensitizes IFN-/STAT-1 signaling in human T lymphocytes. Blood 102:2933–2939[Abstract/Free Full Text]
168. Kooijman R, Coppens A 2004 Insulin-like growth factor-I stimulates IL-10 production in human T cells. J Leukoc Biol 76:862–867[Abstract/Free Full Text]
169. Arner P, Einarsson K, Ewerth S, Livingston J 1986 Studies of the human liver insulin receptor in noninsulin-dependent diabetes mellitus. J Clin Invest 77:1716–1718[Medline]
170. Schneider DJ, Sobel BE 1991 Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA 88:9959–9963[Abstract/Free Full Text]
171. Ginsberg HN 2000 Insulin resistance and cardiovascular disease. J Clin Invest 106:453–458[Medline]
172. Wight TN, Merrilees MJ 2004 Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 94:1158–1167[Abstract/Free Full Text]
173. Hsueh WA, Law RE 1999 Insulin signaling in the arterial wall. Am J Cardiol 84:21J–24J[CrossRef]
174. Mather K, Anderson TJ, Verma S 2001 Insulin action in the vasculature: physiology and pathophysiology. J Vasc Res 38:415–422[CrossRef][Medline]
175. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarino LJ 2000 Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 105:311–320[Medline]
176. Jiang ZY, Zhou QL, Chatterjee A, Feener EP, Myers Jr MG, White MF, King GL 1999 Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. Diabetes 48:1120–1130[Abstract]
177. Ballinger M, Nigro J, Frontanilla K, Dart A, Little P 2004 Regulation of glycosaminoglycan structure and atherogenesis. Cell Mol Life Sci 61:1296–1306[CrossRef][Medline]
178. Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J 1996 Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124:261–271[CrossRef][Medline]
179. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP 2000 Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 152:897–907[Abstract/Free Full Text]
180. Hurt-Camejo E, Paredes S, Masana L, Camejo G, Sartipy P, Rosengren B, Pedreno J, Vallve JC, Benito P, Wiklund O 2001 Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 44:2761–2767[CrossRef][Medline]
181. Juhan-Vague I, Thompson SG, Jespersen J 1993 Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb 13:1865–1873[Abstract/Free Full Text]
182. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P 2004 Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 110:1564–1571[Abstract/Free Full Text]
183. Bruun JM, Verdich C, Toubro S, Astrup A, Richelsen B 2003 Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-. Effect of weight loss in obese men. Eur J Endocrinol 148:535–542[Abstract]
184. Festa A, D’Agostino Jr R, Tracy RP, Haffner SM 2002 Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131–1137[Abstract/Free Full Text]
185. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D’Agostino RB, Wilson PW 2000 Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 283:221–228[Abstract/Free Full Text]
186. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE 1993 The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42:945–949[CrossRef][Medline]
187. Nakamura T, Adachi H, Hirai Y, Satoh A, Ohuchida M, Imaizumi T 2003 Association of plasminogen activator inhibitor-1 with insulin resistance in Japan where obesity is rare. Metabolism 52:226–229[CrossRef][Medline]
188. Takanashi K, Inukai T 2000 Insulin resistance and changes in the blood coagulation-fibrinolysis system after a glucose clamp technique in patients with type 2 diabetes mellitus. J Med 31:45–62[CrossRef][Medline]
189. Romano M, Guagnano MT, Pacini G, Vigneri S, Falco A, Marinopiccoli M, Manigrasso MR, Basili S, Davi G 2003 Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab 88:5321–5326[Abstract/Free Full Text]
190. Piemonti L, Calori G, Mercalli A, Lattuada G, Monti P, Garancini MP, Costantino F, Ruotolo G, Luzi L, Perseghin G 2003 Fasting plasma leptin, tumor necrosis factor- receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care 26:2883–2889[Abstract/Free Full Text]
191. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ 2005 Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111:932–939[Abstract/Free Full Text]
192. Illig T, Bongardt F, Schopfer A, Holle R, Muller S, Rathmann W, Koenig W, Meisinger C, Wichmann HE, Kolb H; KORA Study Group 2003 The endotoxin receptor TLR4 polymorphism is not associated with diabetes or components of the metabolic syndrome. Diabetes 52:2861–2864[Free Full Text]
193. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H 1994 Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441–9445[Abstract/Free Full Text]
194. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H 1990 Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 87:9010–9014[Abstract/Free Full Text]
195. Bartnik M, Malmberg K, Hamsten A, Efendic S, Norhammar A, Silveira A, Tenerz A, Ohrvik J, Ryden L 2004 Abnormal glucose tolerance—a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med 256:288–297[CrossRef][Medline]
196. Sasso FC, Carbonara O, Nasti R, Campana B, Marfella R, Torella M, Nappi G, Torella R, Cozzolino D 2004 Glucose metabolism and coronary heart disease in patients with normal glucose tolerance. JAMA 291:1857–1863[Abstract/Free Full Text]
197. Syvanne M, Ahola M, Lahdenpera S, Kahri J, Kuusi T, Virtanen KS, Taskinen MR 1995 High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J Lipid Res 36:573–582[Abstract]
198. Pascot A, Lemieux I, Prud’homme D, Tremblay A, Nadeau A, Couillard C, Bergeron J, Lamarche B, Despres JP 2001 Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 42:2007–2014[Abstract/Free Full Text]
199. Lamarche B, Lemieux I, Despres JP 1999 The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 25:199–211[Medline]
200. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L 2001 The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 17:189–212[CrossRef][Medline]
201. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N, D’Agostino Sr RB, Wilson PW; Framingham Offspring Study 2001 Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care 24:1403–1410[Abstract/Free Full Text]
202. Gillum R 2003 Distribution of serum total homocysteine and its association with diabetes and cardiovascular risk factors of the insulin resistance syndrome in Mexican American men: The Third National Health and Nutrition Examination Survey. Nutr J 2:6[CrossRef][Medline]

This article has been cited by other articles:

				B. Hemmingsen, S. S Lund, J. Wetterslev, and A. Vaag Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes Eur. J. Endocrinol., July 1, 2009; 161(1): 1 - 9. [Abstract] [Full Text] [PDF]

				C Giannini, T de Giorgis, A Scarinci, I Cataldo, M L Marcovecchio, F Chiarelli, and A Mohn Increased carotid intima-media thickness in pre-pubertal children with constitutional leanness and severe obesity: the speculative role of insulin sensitivity, oxidant status, and chronic inflammation Eur. J. Endocrinol., July 1, 2009; 161(1): 73 - 80. [Abstract] [Full Text] [PDF]

				A. B. M. Reddy, K. V. Ramana, S. Srivastava, A. Bhatnagar, and S. K. Srivastava Aldose Reductase Regulates High Glucose-Induced Ectodomain Shedding of Tumor Necrosis Factor (TNF)-{alpha} via Protein Kinase C-{delta} and TNF-{alpha} Converting Enzyme in Vascular Smooth Muscle Cells Endocrinology, January 1, 2009; 150(1): 63 - 74. [Abstract] [Full Text] [PDF]

				N. Stefan, K. Kantartzis, and H.-U. Haring Causes and Metabolic Consequences of Fatty Liver Endocr. Rev., December 1, 2008; 29(7): 939 - 960. [Abstract] [Full Text] [PDF]

				S. J. Nicholls, E. M. Tuzcu, S. Kalidindi, K. Wolski, K.-W. Moon, I. Sipahi, P. Schoenhagen, and S. E. Nissen Effect of Diabetes on Progression of Coronary Atherosclerosis and Arterial Remodeling: A Pooled Analysis of 5 Intravascular Ultrasound Trials J. Am. Coll. Cardiol., July 22, 2008; 52(4): 255 - 262. [Abstract] [Full Text] [PDF]

				D. J. Betteridge, R. A. DeFronzo, and R. J. Chilton PROactive: time for a critical appraisal Eur. Heart J., April 2, 2008; 29(8): 969 - 983. [Abstract] [Full Text] [PDF]

				R. S. Vasan What is an abnormal blood glucose level? Combining lessons from epidemiology and in vivo plaque imaging. J. Am. Coll. Cardiol. Img., January 1, 2008; 1(1): 46 - 48. [Full Text] [PDF]

				G. Steiner Atherosclerosis in type 2 diabetes: a role for fibrate therapy? Diabetes and Vascular Disease Research, December 1, 2007; 4(4): 368 - 374. [Abstract] [PDF]

				S. K. Sze, D. P. V. de Kleijn, R. C. Lai, E. Khia Way Tan, H. Zhao, K. S. Yeo, T. Y. Low, Q. Lian, C. N. Lee, W. Mitchell, et al. Elucidating the Secretion Proteome of Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Mol. Cell. Proteomics, October 1, 2007; 6(10): 1680 - 1689. [Abstract] [Full Text] [PDF]

				K. Kisfalvi, O. Rey, S. H. Young, J. Sinnett-Smith, and E. Rozengurt Insulin Potentiates Ca2+ Signaling and Phosphatidylinositol 4,5-Bisphosphate Hydrolysis Induced by Gq Protein-Coupled Receptor Agonists through an mTOR-Dependent Pathway Endocrinology, July 1, 2007; 148(7): 3246 - 3257. [Abstract] [Full Text] [PDF]

				G. Li, E. J. Barrett, M. O. Barrett, W. Cao, and Z. Liu Tumor Necrosis Factor-{alpha} Induces Insulin Resistance in Endothelial Cells via a p38 Mitogen-Activated Protein Kinase-Dependent Pathway Endocrinology, July 1, 2007; 148(7): 3356 - 3363. [Abstract] [Full Text] [PDF]

				P. D. Anderson, N. N. Mehta, M. L. Wolfe, C. C. Hinkle, L. Pruscino, L. L. Comiskey, J. Tabita-Martinez, K. F. Sellers, M. R. Rickels, R. S. Ahima, et al. Innate Immunity Modulates Adipokines in Humans J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2272 - 2279. [Abstract] [Full Text] [PDF]

				A. Fischoeder, H. Meyborg, D. Stibenz, E. Fleck, K. Graf, and P. Stawowy Insulin augments matrix metalloproteinase-9 expression in monocytes Cardiovasc Res, March 1, 2007; 73(4): 841 - 848. [Abstract] [Full Text] [PDF]

				A. E. Silver, S. D. Beske, D. D. Christou, A. J. Donato, K. L. Moreau, I. Eskurza, P. E. Gates, and D. R. Seals Overweight and Obese Humans Demonstrate Increased Vascular Endothelial NAD(P)H Oxidase-p47phox Expression and Evidence of Endothelial Oxidative Stress Circulation, February 6, 2007; 115(5): 627 - 637. [Abstract] [Full Text] [PDF]

				S. Basili, G. Pacini, M. T. Guagnano, M. R. Manigrasso, F. Santilli, C. Pettinella, G. Ciabattoni, C. Patrono, and G. Davi Insulin Resistance as a Determinant of Platelet Activation in Obese Women J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2531 - 2538. [Abstract] [Full Text] [PDF]

				V. R. Drel, N. Mashtalir, O. Ilnytska, J. Shin, F. Li, V. V. Lyzogubov, and I. G. Obrosova The Leptin-Deficient (ob/ob) Mouse: A New Animal Model of Peripheral Neuropathy of Type 2 Diabetes and Obesity Diabetes, December 1, 2006; 55(12): 3335 - 3343. [Abstract] [Full Text] [PDF]

				D. Bruemmer C-Peptide in Insulin Resistance and Vascular Complications: Teaching an Old Dog New Tricks Circ. Res., November 24, 2006; 99(11): 1149 - 1151. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nigro, J. Articles by Little, P. J. Search for Related Content PubMed PubMed Citation Articles by Nigro, J. Articles by Little, P. J.